

Social Media Hashtag:
#NCCN2025

Wi-Fi Access:
Network: **nccn2025**
Password: **nccn2025**

**More to Explore in the
Exhibit Hall: Palms II-III**
Friday, March 28 & Saturday, March 29
7:30 AM – 3:35 PM

Premium Exhibits

Visit exhibits from industry, health information technology companies, NCCN Member Institutions, and more.

General Poster Sessions I & II

Posters will be presented during breakfast, lunch, and breaks on Friday and Saturday.

Follow the Expert Guided Poster Tours

Friday, March 28 & Saturday, March 29

Meet by the posters at 12:25 PM.

Experts will lead guided tours of the posters and discuss research highlights.

Reimbursement Resource Room

Visit and learn about reimbursement help and available services.

Patient Advocacy Pavilion

Visit patient advocacy kiosks representing a range of disease types.

Non-CE Product Theaters

Hear about new products and programs in oncology.

Visit NCCN & NCCN Foundation Booth #415

Learn about NCCN resources for clinicians and patients. Staff will be on hand to answer questions. Explore other new and exciting offerings in this area:

- **NEW NCCN Innovation Center**

Learn about and demo existing products, including NCCN Templates and Library of Compendia. Preview a new and exciting way to earn CE credit for accessing NCCN Guidelines!

- **Headshot Station**

Friday, March 28 | 7:30 AM – 3:30 PM

Smile! Stop by to have your headshot taken by a professional photographer. Photos will be taken on a first-come, first-served basis.

- **Enter to Win**

Drop off completed Poster Session Form(s) to enter to win a **Fire TV Stick 4K**.

Complete the NCCN Trends™ Survey to enter to win **Beats Studio Buds**.

Travel through the NCCN Exhibit Hall, visit at least six booths, and return a completed Exhibitor Passport form to receive a **free prize** while supplies last.




March 28–30
**Annual 2025
Conference**

Caribe Royale Orlando, Orlando, FL



EXHIBIT GUIDE



View Exhibit Hall
Floor Plan

Save These Dates!

**NCCN 2025 Annual Congress:
Hematologic Malignancies™**

Friday, October 10 –
Saturday, October 11, 2025
New location!
Hilton San Diego Bayfront
San Diego, CA

**NCCN 2026 Nursing Program:
Advancing Oncology Nursing™**



Thursday, March 26, 2026
Caribe Royale Orlando, Orlando, FL

NCCN 2026 Annual Conference

Friday, March 27 –
Sunday, March 29, 2026
Caribe Royale Orlando, Orlando, FL

Visit [NCCN.org/events](https://www.nccn.org/events) for more information.

NCCN Guidelines for Patients®



Access 70+ FREE cancer resources

- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Children
- Acute Myeloid Leukemia
- Adolescent and Young Adult Cancer
- Adrenal Tumors
- Anal Cancer
- Anemia and Neutropenia: Low Red and White Blood Cell Counts
- Basal Cell Skin Cancer
- Bladder Cancer
- Blood Clots and Cancer
- Bone Cancer
- Brain Cancer: Glioma
- Breast Cancer: DCIS Breast Cancer
- Breast Cancer: Inflammatory Breast Cancer
- Breast Cancer: Invasive Breast Cancer
- Breast Cancer: Metastatic Breast Cancer
- Breast Cancer Screening and Diagnosis
- Cervical Cancer
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Colon Cancer
- Colorectal Cancer Screening
- Cutaneous B-Cell Lymphomas
- Cutaneous T-Cell Lymphomas
- Diffuse Large B-Cell Lymphomas
- Distress During Cancer Care
- Esophageal Cancer
- Fatigue and Cancer
- Follicular Lymphoma
- Gallbladder and Bile Duct Cancers
- Gastrointestinal Stromal Tumors (GIST)
- Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancers
- Graft-Versus-Host Disease
- Hodgkin Lymphoma
- Hodgkin Lymphoma in Children
- Immunotherapy Side Effects: CAR T-Cell Therapy
- Immunotherapy Side Effects: Immune Checkpoint Inhibitors
- Kidney Cancer
- Liver Cancer
- Lung Cancer Screening
- Mantle Cell Lymphoma
- Marginal Zone Lymphomas
- Malignant Pleural Mesothelioma
- Melanoma
- Mouth Cancer
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms
- Nasopharyngeal Cancer
- Nausea and Vomiting
- Neuroendocrine Tumors
- Non-Small Cell Lung Cancer: Early and Locally Advanced
- Non-Small Cell Lung Cancer: Metastatic
- Ovarian Cancer
- Palliative Care
- Pancreatic Cancer
- Peripheral T-Cell Lymphoma
- Primary Central Nervous System Lymphoma
- Prostate Cancer: Advanced Stage
- Prostate Cancer: Early Stage
- Quitting Smoking
- Rectal Cancer
- Small Bowel Adenocarcinoma
- Small Cell Lung Cancer
- Soft Tissue Sarcoma
- Squamous Cell Skin Cancer
- Stomach Cancer
- Survivorship Care for Cancer-Related Late and Long-Term Effects
- Survivorship Care for Healthy Living
- Systemic Mastocytosis
- Throat Cancer
- Thyroid Cancer
- Uterine Cancer
- Waldenström Macroglobulinemia

Commercial Sponsors

Platinum

[Incyte Corporation](#)

Gold

[Eisai Inc.](#)

[Johnson & Johnson](#)

[Regeneron](#)

Bronze

[AstraZeneca](#)

[BeOne Medicines](#)


[Geron Corporation](#)

[GSK](#)

[Jazz Pharmaceuticals](#)

[LeanTaaS](#)

[Servier Pharmaceuticals](#)



EXHIBITORS

American Cancer Society	426
Astellas Pharma Inc.....	313
AstraZeneca.....	115
Bayer.....	101
BeOne Medicines	217
Cheeky Charity	403
Chemo Mouthpiece.....	414
CVS Specialty	326
Daiichi Sankyo, Inc.....	306
Eisai Inc.	226
Eli Lilly and Company.....	107
Exelixis.....	210
Geron Corporation.....	214
Incyte Corporation.....	123
Jazz Pharmaceuticals	219
<i>JNCCN - Journal of the National</i>	
<i>Comprehensive Cancer Network</i>	<i>407</i>
Johnson & Johnson.....	222
Karyopharm Therapeutics	225
Kite Pharma.....	323
LeanTaaS.....	208
Merck & Co., Inc.	103
*Moffitt Cancer Center.....	404
Novartis Pharmaceuticals Corp.....	124
ONCOassist.....	223
OncoHost.....	202
Oncoscope AI.....	428
Pfizer Oncology.....	302
PharmaEssentia.....	424
PreludeDX.....	320

Recordati Rare Diseases	405
Regeneron	121
*Roswell Park Comprehensive	
Cancer Center.....	416
SkinCure Oncology.....	300
Spectrum Pharmaceuticals.....	410
*Stanford Health Care.....	402
Stemline Therapeutics - Commercial	324
Stemline Therapeutics - Medical.....	205
Sun Pharma.....	113
Taiho Oncology, Inc.....	318
Takeda Oncology	109
The Oncology Nutrition Dietetic	
Practice Group.....	325
UroGen Medical Affairs	408

REIMBURSEMENT RESOURCE ROOM

Bayer Health Care	R-2
BeOne Medicines	R-10
Incyte Corporation.....	R-14
Johnson & Johnson.....	R-1
Kite Pharma.....	R-12
Lantheus.....	R-9
Regeneron	R-11
Stemline Therapeutics,	
A Menarini Company	R-4

PATIENT ADVOCACY PAVILION

American Indian Cancer Foundation	A-2
Bladder Cancer Advocacy Network	
(BCAN).....	A-13

Cholangiocarcinoma Foundation.....	A-11
Crossroads4Hope.....	A-17
Global Colon Cancer Association	A-16
G02 for Lung Cancer	A-12
Jacqueline Rush Foundation.....	A-5
LUNgevity Foundation.....	A-3
My Faulty Gene.....	A-14
OUCH-I Oncology Advocates	
United for Climate and	
Health-International	A-6
PAN Foundation	A-15
Say Yes to Hope.....	A-10
Sharsheret	A-9
Support for People with Oral and Head	
and Neck Cancer (SPOHNC)	A-7
The Leukemia & Lymphoma	
Society	A-1
Tigerlily Foundation	A-8
Triage Cancer.....	A-4

NCCN & NCCN Foundation 415

- NEW NCCN Innovation Center
- Headshot Station
- Enter to Win Prizes

* NCCN Member Institution

Non-CE Product Theaters*

These non-CE presentations can be viewed on the Virtual Event Platform.
Attendees can also view in-person in the **Product Theater Area**.
No pre-registration is required.

Friday, March 28

7:50 – 8:20 AM

**The Era of Multi-Cancer Early Detection (MCED)
Testing: The Promise, Potential, and Pressing Questions**

Presented by Exact Sciences

12:00 – 12:30 PM

**Properly Diagnosing, Classifying, and Managing
Lower-risk Myelodysplastic Syndromes (MDS)**

Presented by Bristol Myers Squibb

12:35 – 1:05 PM

**Review of Evidence-Based Data For an Antibody-Drug
Conjugate in Combination with a PD-1 Inhibitor
For 1L LA/mUC**

Presented by Pfizer and Astellas

Saturday, March 29

7:50 – 8:20 AM

**Time Is Critical: Light Chain (AL) Amyloidosis Is Hiding
in Your Clinic**

Presented by Alexion

12:00 – 12:30 PM

**A Treatment Option for Certain Patients With Late-Stage
EGFR Mutation-Positive NSCLC**

Presented by AstraZeneca

12:35 – 1:05 PM

**HER2 Expression Informs Clinical Decision Making in
HER2-Low mBC**

Presented by Daiichi Sankyo and AstraZeneca

*The information and views expressed in these presentations are solely that of the presenter, and do not necessarily reflect the position and policies of NCCN. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

Patient Advocacy Pavilion Sponsors

Emerald

[AstraZeneca](#)

[BeOne Medicines](#)

[Coherus BioSciences](#)

[Eisai Inc.](#)

[Incyte Corporation](#)

[Johnson & Johnson](#)

[Servier Pharmaceuticals](#)

Topaz

[AbbVie](#)

[Cencora](#)

[GSK](#)

[Lantheus](#)

[Regeneron](#)



**NOW
AVAILABLE**

For patients who have had a suboptimal response to T- and B-cell–modulating therapies¹⁻³

Make a change in cGVHD treatment strategy and provide rapid, durable responses^{1,2}

Niktimvo™ (axatilimab-csfr) is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.

INDICATIONS AND USAGE

Niktimvo™ (axatilimab-csfr) is a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

Niktimvo™ (axatilimab-csfr) can cause infusion-related reactions. Infusion-related reactions, including hypersensitivity reactions, occurred in 18% of patients who received Niktimvo in the clinical trial (AGAVE-201), with Grade 3 or 4 reactions in 1.3%.

Premedicate with an antihistamine and an antipyretic for patients who have previously experienced an infusion-related reaction to Niktimvo. Monitor patients for signs and symptoms of infusion-related reactions, including fever, chills, rash, flushing, dyspnea, and hypertension. Interrupt or slow the rate of infusion or permanently discontinue Niktimvo based on severity of the reaction.

Embryo-Fetal Toxicity

Based on its mechanism of action, Niktimvo may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with Niktimvo and for 30 days after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 44% of patients who received Niktimvo (N=79). Serious adverse reactions in > 2 patients included infection (pathogen unspecified) (14%), viral infection (14%), and respiratory failure (5.1%). Permanent discontinuation of Niktimvo due to an adverse reaction occurred in 10% of patients and dose reduction due to adverse reaction occurred in 8% of patients. Dose interruptions due to an adverse reaction occurred in 44% of patients. The adverse reactions leading to dose interruption in > 2 patients were viral infection, infection (pathogen unspecified), bacterial infection, musculoskeletal pain, and pyrexia.

The most common (≥ 15%) adverse reactions, including laboratory abnormalities, were increased aspartate aminotransferase (AST), infection (pathogen unspecified), increased alanine aminotransferase (ALT), decreased phosphate, decreased hemoglobin, viral infection, increased gamma glutamyl transferase (GGT), musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased creatine phosphokinase (CPK), increased alkaline phosphatase (ALP), nausea, headache, diarrhea, cough, bacterial infection, pyrexia, and dyspnea.

Please see Brief Summary of Full Prescribing Information for Niktimvo on the following pages.

Primary endpoint: ORR by cycle 7, day 1*†

75% (59/79) with Niktimvo 0.3 mg/kg Q2W (95% CI, 64-84)¹

1.5 months Median time to first response in patients who had an overall response^{1,2}

60% of patients maintained responses for >1 year^{1,2‡§||}

Broadly demonstrated **disease control** in **all organs studied**^{2§¶}

The safety and efficacy of Niktimvo were studied in the AGAVE-201 trial, a randomized, open-label, multicenter phase 2 study in patients with cGVHD who had failed 2 or more prior lines of therapy. A total of 79 patients were treated with Niktimvo 0.3 mg/kg Q2W until disease progression, lack of response by 9 months, or unacceptable toxicity.^{1,4}

“ I think this is a really nice breakthrough in the GVHD treatment landscape. Targeting T- and B-cell pathways is not always sufficient. Having a different pathway to target could be helpful for patients.

Catherine J. Lee, MD, MS, GVHD Expert



Discover what Niktimvo can do for your patients with cGVHD



*ORR was defined as the proportion of patients who achieved a complete or partial response as defined by 2014 NIH consensus criteria. The ORR was assessed by the number of participants with objective response by cycle 7 (upon the first six 28-day cycles), day 1.¹

†Statistical significance was achieved if the lower bound of the 95% CI exceeded 30%.²

‡In patients who achieved response, no death or new systemic therapy initiation occurred in 60% (95% CI, 43-74) of patients for at least 12 months since response.¹

§Duration of response and ORR by organ affected were prespecified secondary endpoints that were not powered for statistical significance and are therefore considered exploratory.⁵

||Organ-specific responses were evaluated using baseline cGVHD severity as a reference.²

¶Disease control is defined as complete or partial response to treatment.

CI=confidence interval; NIH=National Institutes of Health; ORR=overall response rate; Q2W=every 2 weeks.

Clinically relevant adverse reactions in < 10% of patients who received Niktimvo included:

- *Eye disorders:* periorbital edema
- *Skin and subcutaneous skin disorders:* pruritus
- *Vascular disorders:* hypertension

Immunogenicity: Anti-Drug Antibody–Associated Adverse Reactions

Across treatment arms in patients with cGVHD who received Niktimvo in clinical trials, among the patients who developed anti-drug antibodies (ADAs), hypersensitivity reactions occurred in 26% (13/50) of patients with neutralizing antibodies (NAb) and in 4% (2/45) of those without NAb.

USE IN SPECIFIC POPULATIONS

Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 30 days after the last dose of Niktimvo.

Females and Males of Reproductive Potential

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating Niktimvo.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with Niktimvo and for 30 days after the last dose of Niktimvo.

DOSAGE AND ADMINISTRATION

Dosage Modifications for Adverse Reactions

Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), creatine phosphokinase (CPK), amylase, and lipase prior to the start of Niktimvo therapy, every 2 weeks for the first month, and every 1 to 2 months thereafter until abnormalities are resolved. See Table 1 in the Prescribing Information for more recommendations.

References: 1. Niktimvo Prescribing Information. Wilmington, DE: Incyte Corporation. 2. Wolff D, Cutler C, Lee SJ, et al; for the AGAVE-201 Investigators. Axatilimab in recurrent or refractory chronic graft-versus-host disease. *N Engl J Med.* 2024;391(11):1002-1014. Supplementary appendix available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2401537>. 3. Zeiser R, Lee SJ. Three US Food and Drug Administration–approved therapies for chronic GVHD. *Blood.* 2022;139(11):1642-1645. 4. A study of axatilimab at 3 different doses in participants with chronic graft versus host disease (cGVHD) (AGAVE-201). ClinicalTrials.gov. Updated October 10, 2024. Accessed October 11, 2024. <https://clinicaltrials.gov/study/NCT04710576>. 5. Data on file. Incyte Corporation. Wilmington, DE.



Niktimvo and the Niktimvo logo are trademarks of Incyte.
Incyte and the Incyte logo are registered trademarks of Incyte.
Niktimvo (axatilimab) is licensed to Incyte from Syndax.
© 2024, Incyte. 01/25

MAT-AXA-00041



BRIEF SUMMARY: For Full Prescribing Information, see package insert.

INDICATIONS AND USAGE: NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

NIKTIMVO can cause infusion-related reactions. Infusion-related reactions, including hypersensitivity reactions, occurred in 18% of patients who received NIKTIMVO in the clinical trial (AGAVE-201), with Grade 3 or 4 reactions in 1.3% [see Adverse Reactions (6.1) in Full Prescribing Information].

Premedicate with an antihistamine and an antipyretic for patients who have previously experienced an infusion-related reaction to NIKTIMVO [see Dosage and Administration (2.2) in Full Prescribing Information]. Monitor patients for signs and symptoms of infusion-related reactions, including fever, chills, rash, flushing, dyspnea, and hypertension. Interrupt or slow the rate of infusion or permanently discontinue NIKTIMVO based on severity of the reaction [see Dosage and Administration (2.2) in Full Prescribing Information].

Embryo-Fetal Toxicity

Based on its mechanism of action, NIKTIMVO may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with NIKTIMVO and for 30 days after the last dose [see Use in Specific Populations (8.1, 8.3) in Full Prescribing Information].

ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling.

- Infusion-Related Reactions [see Warnings and Precautions (5.1) in Full Prescribing Information]

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Chronic Graft-Versus-Host Disease

The safety of NIKTIMVO was evaluated in 79 adult and pediatric patients with cGVHD treated with NIKTIMVO 0.3 mg/kg intravenously every 2 weeks in the AGAVE-201 trial [see Clinical Studies (14) in Full Prescribing Information]. The median duration of treatment was 10.3 months (range: 0.5 to 28.6 months), and 73.4% were treated for more than 6 months.

Serious adverse reactions occurred in 44% of patients who received NIKTIMVO. Serious adverse reactions in more than 2 patients included infection (pathogen unspecified), viral infection, and respiratory failure. Permanent discontinuation of NIKTIMVO due to an adverse reaction occurred in 10% of patients and dose reduction due to adverse reaction occurred in 8% of patients. Dose interruptions due to an adverse reaction occurred in 44% of patients. The adverse reactions leading to dose interruption in more than 2 patients were viral infection, infection (pathogen unspecified), bacterial infection, musculoskeletal pain, and pyrexia.

The most common (≥ 15%) adverse reactions, including laboratory abnormalities, were increased AST, infection (pathogen unspecified), increased ALT, decreased phosphate, decreased hemoglobin, viral infection, increased gamma glutamyl transferase (GGT), musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased CPK, increased ALP, nausea, headache, diarrhea, cough, bacterial infection, pyrexia, and dyspnea.

Table 1 summarizes the nonlaboratory adverse reactions in AGAVE-201.

Table 1: Adverse Reactions in ≥ 10% of Patients With cGVHD Who Received NIKTIMVO in AGAVE-201

Adverse Reaction	NIKTIMVO 0.3 mg/kg intravenously every 2 weeks (N = 79)	
	All Grades (%)	Grades 3-4 (%)
Infections and infestations		
Infection (pathogen unspecified) ^a	57	14
Viral infection ^b	43	15
Bacterial infection ^c	15	8
Musculoskeletal and connective tissue disorders		
Musculoskeletal pain ^d	35	3
General disorders and administration site conditions		
Fatigue ^e	32	4
Pyrexia	15	1
Edema ^f	13	1
Gastrointestinal disorders		
Nausea ^g	23	3
Diarrhea ^h	18	5
Nervous system disorders		
Headache ⁱ	20	1
Dizziness ^j	11	0
Respiratory, thoracic and mediastinal disorders		
Cough ^k	18	0
Dyspnea ^l	15	3
Immune system disorders		
Drug hypersensitivity ^m	13	3
Metabolism and nutrition disorders		
Decreased appetite	11	4
Vascular disorders		
Hemorrhage ⁿ	11	1
Skin and subcutaneous tissue disorders		
Rash ^o	10	0

Graded according to NCI CTCAE v5.0.

^a Includes abscess jaw, atypical pneumonia, bacteremia, bronchitis, conjunctivitis, cystitis, device-related infection, enterocolitis infectious, gastroenteritis, gastrointestinal infection, groin abscess, hordeolum, liver abscess, nasopharyngitis, otitis media, otitis media acute, pneumonia, respiratory tract infection, rhinitis, sepsis, sinusitis, tooth infection, upper respiratory tract infection, urinary tract infection, and wound infection.

^b Includes adenoviral upper respiratory infection, BK virus infection, COVID-19, coronavirus infection, enterovirus infection, gastroenteritis astroviral, gastroenteritis viral, herpes simplex, herpes zoster, influenza, metapneumovirus bronchiolitis, metapneumovirus infection, norovirus infection, oral viral infection, parainfluenza viral bronchitis, parainfluenza virus infection, respiratory syncytial virus infection, rhinovirus infection, viral infection, and viral upper respiratory tract infection.

^c Includes bacterial diarrhea, bacterial vaginosis, campylobacter gastroenteritis, campylobacter infection, cellulitis, clostridium difficile colitis, clostridium difficile infection, enterococcal infection, erysipelas, hemophilus infection, lower respiratory tract infection bacterial, pseudomonas skin infection, staphylococcal bacteremia, staphylococcal infection, stentrophomonas infection, streptococcal infection, and urinary tract infection enterococcal.

^d Includes arthralgia, back pain, flank pain, musculoskeletal pain, myalgia, pain in extremity.

^e Includes asthenia, fatigue, and malaise.

^f Includes localized edema and peripheral edema.

^g Includes nausea and vomiting.

^h Includes colitis and diarrhea.

ⁱ Includes headache and migraine.

^j Includes dizziness and dizziness postural.

^k Includes cough and productive cough.

^l Includes dyspnea and dyspnea exertional.

^m Includes bronchospasm, flushing, hot flush, hypersensitivity, infusion-related hypersensitivity reaction, infusion-related reaction, and urticaria.

ⁿ Includes contusion, epistaxis, hematochezia, hematoma, and vaginal hemorrhage.

^o Includes dermatitis bullous, dermatitis exfoliative generalized, rash, and rash maculo-papular.

Clinically relevant adverse reactions in < 10% of patients who received NIKTIMVO included:

- *Eye disorders:* periorbital edema
- *Skin and subcutaneous skin disorders:* pruritus
- *Vascular disorders:* hypertension

Table 2 summarizes the laboratory abnormalities in AGAVE-201.

Table 2: Selected Laboratory Abnormalities in Patients with cGVHD Who Received NIKTIMVO in AGAVE-201

Laboratory Abnormality	NIKTIMVO 0.3 mg/kg intravenously every 2 weeks (N = 79)	
	All Grades ^a (%)	Grade 3 or 4 ^a (%)
Hematology		
Decreased hemoglobin	48	4
Chemistry		
Increased aspartate aminotransferase	61	5
Increased alanine aminotransferase	51	3
Decreased phosphate	51	NA
Increased gamma glutamyl transferase	39	4
Increased lipase	34	3
Increased amylase	32	0
Increased calcium	31	1
Increased alkaline phosphatase	28	0
Increased creatine phosphokinase	25	0

NA = not applicable.

^a The denominator used to calculate the rate varied from 78 to 79 based on the number of patients with at least 1 post-treatment value.

Immunogenicity: Anti-Drug Antibody–Associated Adverse Reactions

In 276 patients with cGVHD who received NIKTIMVO in clinical trials, among the patients who developed anti-drug antibodies (ADAs), hypersensitivity reactions occurred in 26% (13/50) of patients with neutralizing antibodies (NAb) and in 4% (2/45) of those without NAb [see *Clinical Pharmacology (12.6) in Full Prescribing Information*].

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

Based on its mechanism of action, NIKTIMVO may cause fetal harm when administered to pregnant women [see *Clinical Pharmacology (12.1) in Full Prescribing Information*]. There are no available data on the use of NIKTIMVO in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with axatilimab-csfr. Targeted mutation of CSF-1R or CSF-1 in rodent models results in prenatal and perinatal death, deficits in growth, and pleiotropic impact on multiple organ systems, including skeletal and reproductive. Regulation by CSF-1R on non-mononuclear phagocytic cells and macrophages plays a role in the innate immune protection of the fetus and in pregnancy maintenance and embryo-fetal development. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, NIKTIMVO has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

Risk Summary

There are no data on the presence of axatilimab-csfr in human milk or the effects on the breastfed child or milk production. Maternal IgG is known to be

present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 30 days after the last dose of NIKTIMVO.

Females and Males of Reproductive Potential

NIKTIMVO may cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations (8.1) in Full Prescribing Information*].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating NIKTIMVO [see *Use in Specific Populations (8.1) in Full Prescribing Information*].

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with NIKTIMVO and for 30 days after the last dose of NIKTIMVO.

Pediatric Use

The safety and effectiveness of NIKTIMVO for the treatment of cGVHD after failure of at least two prior lines of systemic therapy have been established in pediatric patients weighing at least 40 kg. Use of NIKTIMVO in pediatric patients weighing at least 40 kg is supported by evidence from clinical trials that included 3 children (ages 6 to less than 12 years old) and 5 adolescents (ages 12 to less than 17 years old) [see *Clinical Studies (14) in Full Prescribing Information*]. The safety and effectiveness of NIKTIMVO have not been established in pediatric patients weighing less than 40 kg.

Compared to adult and pediatric patients weighing 40 kg and above, patients weighing less than 40 kg had lower maximum concentration, trough concentration, and average concentration at the same weight-based dosage. Based on findings of thickening of the growth plate and metaphysis and/or degeneration of the growth plate in the femur in animals, monitor bone growth and development in pediatric patients [see *Nonclinical Toxicology (13.2) in Full Prescribing Information*].

Geriatric Use

Of the 79 patients with cGVHD treated with NIKTIMVO, 21 (26.6%) were 65 years and older, and 2 (2.5%) were 75 years and older [see *Clinical Studies (14) in Full Prescribing Information*]. No overall differences in the safety or effectiveness of NIKTIMVO have been observed between patients 65 years of age and older and younger patients.

Manufactured by:
Incyte Corporation
Wilmington, DE 19803
U.S. License No. 2228

Licensed from:
Syndax Pharmaceuticals, Inc.
Waltham, MA 02451



NIKTIMVO and the NIKTIMVO logo are trademarks of Incyte.
Patent Information: www.incyte.com/patents
© 2025 Incyte Corporation. All rights reserved.
Issued: January 2025 PLR-AXA-00003



Not actual patients



LENVIMA[®]
(lenvatinib) capsules | 10 mg and 4 mg

**Explore the data at
LENVIMAHCP.com**



LENVIMA[®] is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2023 Eisai Inc. All rights reserved. Printed in USA/September 2023 LENV-US9910



**Is Roswell Park the
right **one** for you?**

Roswell Park's Department of Nursing boasts a dynamic staff of over 800 strong, working together to deliver exceptional care to people with cancer and their families. As an essential pillar of a nationally ranked comprehensive cancer center, our nursing contributes to evidence-based practices with nurse-driven research, initiates educational programs and mentors and develops the next generation of nursing leaders.

Visit our booth to discover how Roswell Park is advancing cancer care and research.



apply today!

Scan the QR Code or visit RoswellPark.org/Nursing, to explore exciting career opportunities at Roswell Park.



 **DARZALEX[®]**
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro[®]**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Watch KOL expert series at darzalexhcp.com

Suzanne Reim Fanning, DO




Data rates may apply.

Johnson & Johnson

© Janssen Biotech, Inc. 2024 10/24 cp-434910v2

 **LIBTAYO**[®]
(cemiplimab-rwlc)
Injection 350 mg



Patient portrayal

**Explore the clinical profile of LIBTAYO
across multiple indications**

**Visit Regeneron Booth 121 at
National Comprehensive Cancer Network[®]
(NCCN[®]) 2025 Annual Conference
or [Libtayohcp.com](https://libtayohcp.com)**

March 28–30, 2025
Caribe Royale Orlando
Orlando, FL

Please scan QR code
to learn more



REGENERON[®]

© 2023 Regeneron Pharmaceuticals, Inc. All rights reserved.
US.LIB.23.09.0002 09/23

Explore the clinical profile of LIBTAYO across multiple indications



To learn more scan here
or visit LIBTAYOhcp.com





Offering support throughout the treatment journey.

Learn more at
LIBTAYOSurround.com



REGENERON[®]

© 2024 Regeneron Pharmaceuticals, Inc. All rights reserved.
US.LIB.24.03.0100 06/24

Learn more about AstraZeneca



IMFINZI[®]
durvalumab
Injection for Intravenous Use 50 mg/mL

IMJUDO[®]
tremelimumab-actl
Injection for Intravenous Use 20 mg/mL



CALQUENCE[®]
acalabrutinib 100 mg tablets



TAGRISO[®]
osimertinib



Lynparza[®]
olaparib
tablets 150 mg



Truqap[™]
capivasertib



Please scan for complete Prescribing Information, including Boxed WARNINGS and Medication Guide, or visit www.ENHERTUHCP.com

ENHERTU[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Please see Important Safety Information and full Prescribing Information, including Boxed WARNINGS, and Medication Guide, available at our booth & at www.ENHERTUHCP.com



ENHERTU[®] is a registered trademark of Daiichi Sankyo Company, Limited.
© 2024 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-ENB-3120 02/24

For more information, please visit us at www.astrazeneca-us.com

CALQUENCE, IMFINZI, IMJUDO, LYNPARZA and TAGRISSO are registered trademarks, and TRUQAP is a trademark of the AstraZeneca group of companies.

©2024 AstraZeneca. All rights reserved. US-87235 Last updated 03/24

AstraZeneca

About Our Exhibitors

American Cancer Society **Booth #426**

The American Cancer Society (ACS) is a nationwide, nonprofit organization dedicated to eliminating cancer through research, education, advocacy, and patient support. Founded in 1913, it funds groundbreaking cancer research, provides resources for patients and their families, and works to improve public health policies related to cancer prevention and treatment. The ACS is committed to saving lives and reducing cancer-related deaths.

Astellas Pharma Inc. **Booth #313**

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

AstraZeneca **Booth #115**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on social media @AstraZeneca.

Bayer **Booth #101**

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world.

BeOne Medicines **Booth #217**

BeOne Medicines USA, Inc., formerly known as BeiGene USA, Inc., is a subsidiary of BeiGene, Ltd., a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and

collaborations. We are committed to radically improving access to medicines for far more patients who need them. To learn more, please visit beigene.com/about/beone/.

Chemo Mouthpiece **Booth #414**

Chemo Mouthpiece, LLC. is a device company focused on oncology supportive care. We are excited to show you The Chemo Mouthpiece, a 510(k) cleared device for marketing in the US. It is intended to be used to cool the oral mucosa to reduce the incidence and severity of chemotherapy induced oral mucositis. Historically, oral cryotherapy was used only for short half-life drugs, the Chemo Mouthpiece shifts that paradigm by studying its efficacy in multiple long half-life drugs, giving you & your patients a better choice! Visit our booth #414 and our poster presentation on March 28 for more information.

CVS Specialty **Booth #326**

CVS Specialty is a pharmacy that provides medications and support for patients with chronic and rare conditions. They offer services like Care Teams, infusion services, and financial assistance.

Daiichi Sankyo, Inc. **Booth #306**

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.

Our success comes from experts in collaboration: our people, scientists, health care providers, advocates – and patients themselves.

Building on a 120-year heritage and a culture of innovation, we're forging better futures through medicine for people everywhere. Together, we are creating new standards of care—our contribution to the enrichment of quality of life around the world. Please visit www.daiichisankyo.us.

Eisai Inc. **Booth #226**

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer's disease and other neurodegenerative conditions. Our hhc mission is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

BRONZE

BRONZE

GOLD

About Our Exhibitors

To learn more about Eisai Inc., please visit us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

Eli Lilly and Company **Booth #107**

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. To learn more, visit [Lilly.com](https://lilly.com).

Flatiron Health **Booth #210**

Flatiron Health partners with NCCN Academic Medical Centers to harness the power of real-world oncology data, advancing research, clinical trials, and quality improvement initiatives. Through machine learning and expert curation, we transform patient experiences into actionable insights, enabling AMCs to drive innovation in cancer care. By integrating research and care, we help create a more modern, connected oncology ecosystem that accelerates discoveries and improves outcomes for every person with cancer.

Geron Corporation **Booth #214**

We are committed to extending and enhancing the lives of people living with blood cancers. Scientific research has shown that telomerase activity is increased in malignant stem and progenitor cells in the bone marrow. Inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells. Geron is exploring the broad potential of telomerase inhibition across multiple hematologic malignancies. Our science, expertise and commitment to transforming the treatment landscape of blood cancers drives our single-minded urgency to deliver innovative therapies to patients.

BRONZE

PLATINUM

Incyte Corporation **Booth #123**

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information, visit Incyte.com and follow @Incyte.

BRONZE

Jazz Pharmaceuticals **Booth #219**

At Jazz Pharmaceuticals, our purpose is to innovate to transform the lives of patients and their families.

We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options – so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what's possible – to make the "small wins" big again.

JNCCN—Journal of the National Comprehensive Cancer Network **Booth #407**

More than 25,000 oncologists and other cancer care professionals across the United States read *JNCCN—Journal of the National Comprehensive Cancer Network*. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, oncology health services research, and translational medicine. *JNCCN* features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), solicited review articles elaborating on guideline recommendations, health services research, and case reports highlighting molecular insights in patient care. *JNCCN* is dedicated to improving the quality of cancer care locally, nationally, and internationally while enhancing the collaboration between academic medicine and the community physician. *JNCCN* is indexed by MEDLINE/PubMed, Chemical Abstracts, Embase, EmCare, and Scopus. The 2023 Impact Factor for *JNCCN* is 14.8.

NOW APPROVED
IN A NEW 1L INDICATION



TEVIMBRA[®]

(tislelizumab-jsgr)

Injection, for intravenous use 10 mg/mL



BE THE FIRST TO SEE THE DATA
Scan here for 1L results that can't be ignored.

1L, first line.

TEVIMBRA and BeiGene are registered trademarks owned by BeiGene, Ltd. or its affiliates.
© BeiGene, Ltd. 2024 All Rights Reserved. 0424-TEV-PRC-034 01/25



RYTELOTM
(imetelstat) for Injection 47 mg
188 mg

Learn more at RYTELOHCP.com



C-US-RYT-IM-0125 June 2024 © 2024 Geron Corp.
All rights reserved. GERON, GERON logo, RYTELO, and
RYTELO logo are trademarks of Geron Corporation.



About Our Exhibitors

GOLD

Johnson & Johnson

Booth #222

At Johnson & Johnson, we believe health is everything. As a focused healthcare company, with expertise in Innovative Medicine and MedTech, we're empowered to tackle the world's toughest health challenges, innovate through science and technology, and transform patient care.

Karyopharm Therapeutics

Booth #225

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering novel first-in-class cancer therapies and dedicated to the discovery, development, and commercialization of drugs to treat cancer. We are recognized leaders in XPO1 inhibition. We believe in the extraordinary – in the dedication to positively impact patient lives and treat cancer.

Kite Pharma

Booth #323

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing.

For more information on Kite, please visit www.kitepharma.com.

LeanTaaS

Booth #208

LeanTaaS is the leading provider of AI-powered and cloud-based capacity management, staffing, and patient flow software and services for health systems. Our iQueue products for operating rooms, infusion centers, and inpatient units use Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively in response to avoid operational bottlenecks before they happen.

The result? Expensive assets are utilized better, hospital ROI improves, patient access increases, and clinicians work at the top of their license with reduced administrative burden.

Merck & Co., Inc.

Booth #103

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck

is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

* Moffitt Cancer Center

Booth #404

Moffitt Cancer Center is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT and or visit MOFFITT.org.

Novartis Pharmaceuticals Corp.

Booth #124

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

ONCOassist

Booth #223

ONCOassist is the #1 app for oncology healthcare professionals, providing fast, reliable, and evidence-based tools to support clinical decision-making. Trusted by more than 90k oncology HCPs globally, it offers TNM staging calculators, prognostic scores, drug interaction checks, and up-to-date oncology protocols - all in one intuitive platform. Stay informed with the latest oncology research while streamlining patient care. ONCOassist is available free of charge to oncology HCPs, ensuring instant access to essential oncology resources. Download ONCOassist today from either app store. The ultimate oncology support tool.

OncoHost

Booth #202

OncoHost is a technology company dedicated to advancing precision oncology through innovative diagnostics that tackle cancer treatment resistance. Its PROphet® platform, a plasma-based tool powered by proteomic pattern recognition, bioinformatics, and AI, enhances oncologists' clinical decision-making. The company's PROphetNSCLC™ test, available across the U.S., guides immunotherapy treatment choices for stage IV patients using a single pre-treatment blood sample. PROphet® shows potential in other indications, including melanoma, RCC, TNBC, and more. Supported by a global trial spanning 40+

BRONZE

About Our Exhibitors

sites and enrolling 1,700+ patients, OncoHost is setting new standards in biomarker-driven, patient-centered cancer care.

Oncoscope AI **Booth #428**

Oncoscope-AI is a comprehensive medical decision-support tool developed by a team of oncology scientists and AI experts. The software conducts daily Cochrane-level literature reviews supported by an agentic system of large language models, extracting 32 key variables from each relevant oncology publication into a structured database. 100% human reviewed and cross-checked, the results data are integrated with treatment paths from national guidelines and cross-linked with FDA and clinical trial registries. Designed for oncology professionals, the intuitive, interactive platform offers individual and institutional subscription options delivering real-time clinical data, empowering oncologists to make timely informed treatment decisions that improve patient outcomes.

Pfizer Oncology **Booth #302**

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients' lives.

PharmaEssentia **Booth #424**

PharmaEssentia is a growing global biopharmaceutical innovator focused on delivering effective new biologics in hematology / oncology, and other cancers.

PreludeDx **Booth #320**

DCISionRT by PreludeDx is the only DCIS test that predicts radiation therapy (RT) benefit in women undergoing breast conserving surgery (BCS). The test provides a Decision Score along a continuum from 0 to 10, that stratifies a woman's 10-yr risk of local recurrence as low, elevated or residual risk. DCISionRT combines seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions

between individual biologic factors to provide a better assessment of the patient's individual tumor biology. The personalized results help patients and physicians make more informed treatment decisions and facilitate the shared decision-making process.

Recordati Rare Diseases **Booth #405**

Regeneron **Booth #121**

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.

* **Roswell Park Comprehensive Cancer Center** **Booth #416**

Since 1898, Roswell Park Comprehensive Cancer Center has provided care marked by compassion, innovation and effectiveness. Operating in Buffalo and across our multi-state community network, we are the only National Cancer Institute-designated comprehensive cancer center in Upstate NY — recently awarded an exceptional rating from the NCI. Our team helps set care standards through leadership roles with the NCCN and consistently earns patient satisfaction scores among the highest in the country. Supported by a nursing department of over 800 nurses, our work integrates many disciplines and strategies, all rooted in how a solution today can lessen cancer's impact tomorrow.

SkinCure Oncology **Booth #300**

SkinCure Oncology is the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure™ Experience, Image-Guided SRT is available from some 500 physicians nationwide, with more than 90,000 patients having been treated. Learn more about the company at SkinCureOncology.com and visit GentleCure.com for helpful consumer and patient information.

* NCCN Member Institution

GOLD

About Our Exhibitors

Spectrum Pharmaceuticals

Booth #410

*** Stanford Health Care**

Booth #402

Stanford Health Care is a leading academic health system and part of Stanford Medicine, which includes the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford. Stanford is renowned for breakthroughs in treating cancer, heart disease, brain disorders and surgical and medical conditions. Whether you're an experienced professional or just beginning your career, Stanford Health Care has a wealth of opportunities to work at the future of medicine. Find the position that inspires you careers.stanfordhealthcare.org.

Stemline Therapeutics

Booth #205 & #324

Stemline Therapeutics, Inc. ("Stemline") a wholly owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need it, with the ultimate goal of improving the lives of those impacted by cancer.

Sun Pharma

Booth #113

Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations.

Taiho Oncology, Inc.

Booth #318

Taiho Oncology specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada.

Takeda Oncology

Booth #109

Takeda Oncology, the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited, is structured to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. Built on a legacy foundation and structured for agility, our leaders have proven experience to drive future growth. We've demonstrated leadership in the treatment of hematologic cancers and solid tumors, and we're now leveraging that expertise to advance cutting-edge science through multiple platforms, partnerships and therapeutic approaches. We are focused on collaborating with leading scientific teams around the globe to accelerate remarkable innovation, including by leveraging the power of innate immunity to enhance and broaden the impact of immunotherapy. We complement our deep in-house expertise with a network of symbiotic external partnerships to unlock the most promising science wherever it emerges. We fuel our relationships with academic, biotechnology and pharmaceutical partners with mutual respect, shared knowledge, scientific rigor and agility to find the best way to attack cancer. We are structured to ensure a tight connection from research to development to commercialization to rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.

Takeda Oncology: We aspire to cure cancer with inspiration from patients and innovation from everywhere. For more information, visit www.takedaoncology.com. Review our social media community guidelines: www.takedaoncology.com/social-media-policy.

About Our Exhibitors

The Oncology Nutrition Dietetic Practice Group

Booth #325

The Academy of Nutrition and Dietetics is the premier organization of nutrition professionals in the United States. The Oncology Nutrition Dietetic Practice Group or ON DPG is a dietetic practice group of the Academy. We are a national organization with over 2000 members. The practice of oncology nutrition covers research, prevention, treatment, recovery, palliative care, and hospice. The ON DPG provides dietetic professionals with resources and networking opportunities to deal with the complexities of oncology practice. Members work in clinical, public health, education, and research settings.

UroGen Medical Affairs

Booth #408

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel[®] reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-NMIBC are designed to ablate tumors by non-surgical means.



Oncology Policy Summit



**Tuesday,
May 6, 2025**

Join us in
Washington, D.C.
or Virtually

Primary Care and Oncology Collaboration for Better Patient Outcomes

Explore opportunities to strengthen coordination between primary care and oncology care providers.



Register Now: [NCCN.org/summits](https://www.nccn.org/summits)

Ahead Together

Our expertise in oncology allows us to bring groundbreaking cancer therapies to the patients who need them most.


GSK

© 2025 GSK group of companies or its licensor. All rights reserved. Trademarks are owned by or licensed to the GSK group of companies. PSE-US-3671, February 2025.

 [us.gsk.com](https://www.us.gsk.com)

Operate smarter to reduce patient wait times and nurse burnout

Optimize infusion scheduling, level-load patient flow, and improve experience for patients and staff alike.



Earn \$20K/chair annually.*

Realize 50% reduced wait times*



LEARN MORE

*Based on historical customer outcomes, results vary.

Patient Advocacy Pavilion

American Indian Cancer Foundation

At the American Indian Cancer Foundation (AICAF), we imagine a world where cancer is no longer the leading cause of death for Native people. Through hard work, culturally appropriate community-based programs, and policy change that affords Native people access to the best prevention and treatment strategies. AICAF embraces a solutions-oriented and strength-based approach to addressing the Cancer Care Continuum. At AICAF we envision a day where Native communities are free of the burdens of cancer.

Bladder Cancer Advocacy Network (BCAN) A-13

The Bladder Cancer Advocacy Network, or BCAN, was founded in 2005 and is the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease. BCAN is on the front lines advocating for greater public awareness and increased funding for research to identify effective treatments and eventually, a cure for bladder cancer.

Cholangiocarcinoma Foundation A-11

The Cholangiocarcinoma Foundation (CCF) is a global nonprofit dedicated to improving the lives of those affected by cholangiocarcinoma, a rare and aggressive bile duct cancer. CCF drives awareness, supports patients and caregivers, and advances research through initiatives like its Patient Registry, mentorship programs, and research fellowships. Collaborating with experts worldwide, CCF has contributed to FDA approvals and innovative treatments. Learn more at curecca.org and join the fight against cholangiocarcinoma.

Crossroads4Hope A-17

Crossroads4Hope offers people diagnosed with cancer and their loved ones, at no charge, a network of resources, information, support, and the professionals fundamental to living with, through, and beyond cancer with strength and hope.

Vision: A world where the best cancer care prioritizes the needs of the whole person and their entire family, including emotional and social wellbeing and practical support people need, regardless of who they are or where they live.

Impact: Crossroads4Hope puts people first, not disease. With empathy and compassion, we enhance people's emotional and social well-being, reducing the burden of cancer for all those affected.

A-2 Global Colon Cancer Association A-16

The Global Colon Cancer Association (GCCA) advocates for equitable access to quality colorectal cancer screenings, testing, treatments, and care, because where you live should not determine whether you can prevent or survive colorectal cancer. As both a membership-based umbrella organization and patient advocacy organization, GCCA amplifies and supports the efforts of our member organizations, develops adaptable advocacy and educational materials for our members, and conducts our own advocacy, education, and patient-centered policy initiatives.

GO2 for Lung Cancer A-12

GO2 for Lung Cancer is at the forefront of everything that's happening in lung cancer. We're the go-to for one-on-one assistance, supportive connections, treatment information, and finding the best care close to home. We're the place to go to learn about the latest research and special initiatives that increase survivorship. We're the source for improving health policies and leading public awareness to shift this disease from one of stigma to one of hope. We are teachers, guides, advocates, and supporters. Confronting lung cancer starts here®. Our services include:

- Helpline, personalized information, support, and referral
- LungMATCH, treatment and clinical trial navigation
- Phone Buddy Program, 1:1 peer support matching
- Lung Cancer Living Room, educational series, featuring experts on a range of lung cancer topics
- Gathering HOPE, a monthly virtual social gathering
- Support Group Network for help finding lung cancer-specific groups
- Educational materials that address a wide variety of subjects

Jacqueline Rush Foundation A-5

The Jacqueline Rush Foundation's mission is to save lives by improving public and medical community awareness of Lynch Syndrome, provide support, education and resources for those with Lynch Syndrome and their families, and raise funds for Lynch Syndrome Research. We are building a community so those with Lynch Syndrome never feel alone.

Patient Advocacy Pavilion

LUNGevity Foundation

A-3

LUNGevity is transforming what it means to be diagnosed and live with lung cancer through research, advocacy, and community. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. Comprehensive resources include a medically vetted website, Patient Gateways for specific types of lung cancer, a HELPLine for personalized support, survivor conferences, and tools to find a clinical trial. All these programs are designed to help us achieve our vision—a world where no one dies of lung cancer.

My Faulty Gene

A-14

My Faulty Gene is a nonprofit organization which provides information and assistance to underrepresented, uninsured, and underinsured individuals whose family medical history suggests genetic testing might be helpful in identifying an increased risk of disease due to a genetic mutation. We believe that everyone in need of germline genetic testing should have access, including family members of individuals with a known mutation.

OUCHE-I Oncology Advocates United for Climate and Health – International

A-6

OUCHE- Int'l (Oncology Advocates United for Health - International) is the only non-profit, nonpartisan volunteer cancer organization whose mission is to advance awareness, actions, and policies that mitigate the effects of climate change on cancer care. Our pillars include advocacy, education and outreach research, cancer care delivery, sustainability, and resilience, and climate justice and health equity. Our members include oncology health care professionals, including physicians, nurses, researchers, other allied health professionals and patient advocates. We currently have over 175 members representing 27 states and 23 different countries, including six oncology professional societies.

PAN Foundation

A-15

As a leading charitable foundation and healthcare advocacy organization, the PAN Foundation is dedicated to accelerating access to treatment for those who need it most and empowering patients on their healthcare journeys. We provide critical financial assistance for treatment costs, advocate for policy solutions that expand access to care, and deliver education on complex topics—all driven by our belief that everyone deserves access to affordable, equitable healthcare.

Say YES to Hope

A-10

Say YES to Hope is changing the world for those who are diagnosed with advanced cancer through outreach, education, support, and hope.

We are committed to serving this underserved population of cancer patients because the association between access to care and support demonstrates increased survival, better outcomes, and improved quality of life. Our revolutionary campaigns in outreach and education help people live more fully in spite of advanced cancer and dramatically enhances the outlook for living with this life limiting diagnosis.

Sharsheret

A-9

Sharsheret is a national not-for-profit organization that supports women and families facing breast or ovarian cancer, or who are at higher diagnostic risk. Our free, confidential support includes access to social workers, genetic counselors, and a range of programs, including financial subsidies, to help women navigate their cancer experiences. Sharsheret has a wide array of educational brochures for you to share with patients and offers free professional training for your team (CE credit may be available). For more information or to order resources, visit us at www.sharsheret.org or call us at (866) 474-2274.

Support for People with Oral and Head and Neck Cancer (SPOHNC)

A-7

Support for People with Oral and Head and Neck Cancer (SPOHNC), founded in 1991 by an oral cancer survivor, is a not-for-profit organization committed to improving the lives of patients and survivors. SPOHNC provides resources, publications, and support to address the medical, emotional, and psychosocial challenges faced by this community. With a focus on awareness and advocacy, SPOHNC connects individuals to vital information and a compassionate support network. Visit www.spoHNC.org to learn more.

Testicular Cancer Awareness Foundation – Virtual only

Testicular Cancer Awareness Foundation is compassionately dedicated to raising awareness and educating the general public about the most common form of cancer in men ages 15-44 and providing lifesaving valuable support for patients, survivors and caregivers. We stress the importance of early detection through the practice of monthly testicular self-exams (TSE) and seek to reduce the great stigma and taboo associated with talking about testicular health through our vital programs and resources.

Patient Advocacy Pavilion

The Leukemia & Lymphoma Society

A-1

The Leukemia & Lymphoma Society (LLS) is the world's largest nonprofit health organization dedicated to funding blood cancer research, support and advocacy. LLS' mission is to cure blood cancer and improve the quality of life for all patients and their families.

LLS provides up-to-date disease and treatment information through its website, multi-format educational resources, and direct support from Information Specialists, Clinical Trial Navigators and Dieticians via the Information Resource Center (IRC), Clinical Trial Support Center (CTSC), and Nutrition Education Services Center (NESC). For more information, visit [LLS.org/PatientSupport](https://lls.org/PatientSupport) or [LLS.org/CE](https://lls.org/CE).

Tigerlily Foundation

A-8

Tigerlily Foundation is a women's health and oncology organization dedicated to supporting young women (15-50) affected by breast and other cancers. We provide education, awareness, advocacy, and empowerment programs to help women navigate their cancer journey.

Our inclusive programs cater to all women impacted by cancer, including those in underserved communities

and those facing health disparities. We incorporate spirituality, holistic approaches, health and wellness, risk reduction, support, and survivorship to promote overall well-being.

Our goal is to empower women to live their best lives before, during, and after cancer. By providing comprehensive support and resources, we aim to make a positive impact on the lives of women affected by cancer, and we strive to create a supportive community that fosters hope, resilience, and empowerment.

Triage Cancer

A-4

Triage Cancer provides education on legal and practical issues that may impact individuals diagnosed with cancer and their caregivers. Provides expert content on issues related to work, insurance, disability benefits, finances, estate planning, medical decision-making, and more. Offers free in-person and online educational events, materials, animated videos, and state-specific resources. Provides free one-on-one help to assist individuals understand their options and possible next steps, as well as [CancerFinances.org](https://www.cancerfinances.org), which helps people navigate finances after cancer.

Reimbursement Resource Room

Regeneron

R-11

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit [www.Regeneron.com](https://www.regeneron.com) to learn more.

General Poster Session I

Hosted by NCCN Oncology Research Program (ORP)

Session I Friday, March 28

Breakfast 7:30 - 8:30 AM | Morning Break 9:45 - 10:05 AM

Lunch 11:55 AM - 1:10 PM | Afternoon Break 3:15 - 3:35 PM

Follow the Expert Guided Poster Tour

Open to all attendees. No pre-registration required. An NCCN Member Institution expert will lead a group of conference attendees and highlight research.

Meet by the posters
in the Exhibit Hall at 12:25 PM.

#	Presenting Author and Institution	Title	Co-Authors	Category
 1	Natalie Johns, BA The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute NCCN Member Institution	Real-World Evidence of Survival in Patients with Metastatic NSCLC Treated with Firstline Immune Checkpoint Inhibitors Beyond Progression	Alexander Rudich, BS; Songzhu Zhao, MS; Kenneth Chian, BS; Po-Lan Su, MD, PhD; Adam Khorasanchi, MD; Jinesh Gheeya, MD, PhD; Daniel Spakowicz, PhD; Lai Wei, PhD; Logan Roof, MD, MS; Asrar Alahmadi, MBBS; Regan Memmott, MD; Jacob Kaufman, MD, PhD; Carolyn Presley, MD; Kai He, MD, PhD; Peter Shields, MD; Christian Rolfo, MD, PhD; David Carbone, MD, PhD; Dwight Owen, MD, MS; Mingjia Li, MD	Clinical Oncology
 2	Sandra Amponsah Frimpong, MD Fred & Pamela Buffett Cancer Center NCCN Member Institution	Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma	Valerie Shostrom, MS; Robert Gregory Bociek, MD, MSc; Matthew Lunning, DO; Christopher D' Angelo, MD; James Olen Armitage, MD; Julie M. Vose, MD, MBA	Clinical Oncology
 3	Malgorzata Gil, PhD Roswell Park Comprehensive Cancer Center NCCN Member Institution	Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model	Tao Yu, PhD; Meera Alderson, BA; Kazuaki Takabe, MD, PhD; Antonio D'Assoro, PhD; Shunqiang Li, PhD; Mateusz Opyrchal, MD, PhD	Pre-Clinical Oncology
 4	Brittany C. Kimball, MD Mayo Clinic Comprehensive Cancer Center NCCN Member Institution	Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic	Minji K. Lee, PhD, MS; Kimberly O. Steinert, BS; Jordan A. Mason, JD, MHA; Wendy A. Hanson, MPH; Wendy A. Allen-Rhoades, MD, PhD; Allison C. Rosenthal, DO; Robert R. McWilliams, MD	Outcomes and Health Services Research
 5	Shlomo A. Koyfman, MD Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Member Institution	Metastasis-free Survival Prediction with the 40-gene Expression Profile Test in Patients with Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines®	Emily S. Ruiz, MD, MPH; Karina Brito, BS; Emily E. Karn, MS; Ray Fodor, BS; Allison T. Vidimos, RPh, MD; Shauna R. Campbell, DO; David M. Wang, MD; Jennifer J. Siegel, PhD; Brian J. Martin, PhD; Jason H. Rogers, MS; Matthew S. Goldberg, MD; Kelsey E. Hirotsu, MD; Nima Gharavi, MD, PhD	Clinical Oncology
 6	Arnab Basu, MD, MPH O'Neal Comprehensive Cancer Center at UAB NCCN Member Institution	Molecular Residual Disease (MRD) Guided Adjuvant Therapy in Renal Cell Carcinoma (RCC) - The MRG GATE RCC - Study	Fady Sidhom, MD; Caleb Hwang, BA; James Ferguson, MD, PhD; Charles Peyton, MD; Sejong Bae, PhD; Deepak Kilari, MD; Arpita Desai, MD; Soroush Rais-Bahrami, MD, MBA	Trials in Progress
 7	Julia L. Agne, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute NCCN Member Institution	SyMPLER Palliative Care: Symptom Monitoring Program Linked to Electronic Referrals to Palliative Care	Madison M. Grogan, MPH; Jason Benedict, MS; Ann Scheck McAlearney, ScD, MS; Carolyn J. Presley, MD, MHS	Trials in Progress
8	Srineil Vuthaluru, MBBS Fred & Pamela Buffett Cancer Center NCCN Member Institution	Does Adjuvant Therapy Improve Survival Following Upfront Esophagectomy? Real World Evidence Based on National Cancer Database Analysis	Collin Dougherty, BS; Quan Ly, MD	Clinical Oncology
9	Sharanya Tripathi, MD Saint Vincent Hospital	Mortality and DALY in Uterine Cancer Patients with High Body Mass Index: A Comparative Study of the United States and Global Data (1990-2021)	Charmi Bhanushali, MD; Jayalekshmi Jayakumar, MD; Vidhi Bhanushali, MBBS; Kalaivani Babu, MD; Srinishant Rajarajan, MD; Arya Mariam Roy, MD	Epidemiology/Risks/Prevention
10	Kelly Hao, BS The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute NCCN Member Institution	Exploring CD30+ Cutaneous Lymphomas: A Retrospective Study on Clinical Outcomes and Prognostic Markers	N/A	Clinical Oncology

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
11	MaryAnn Fragola, DNP <i>New York Cancer and Blood Specialists</i>	Assessment of Community Oncology Palliative and Supportive Care Program in Improving Patient's Quality of Life: A Patients Perspective	N/A	Outcomes and Health Services Research
12	Riccesha Hattin, DO <i>University of Nevada Las Vegas Kirk Kerkorian School of Medicine</i>	Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients with Relapsed/Refractory Multiple Myeloma Treated with Belantamab Mafodotin	Abbas Hussain, MD; Hazem Aboaid, MD; Savannah Schauer, MS-III; Tal Schlesinger, MS-III; Rory Twells, MS-III; Karl Aharonian, MS-III; Ryan Parto, MD; Rodd Rahmani, MD; Chalette Lambert-Swainston, MD; Daniel Thomas Jones, OMS-IV; Ramaditya Srinivasmurthy, OMS-IV; Kyaw Zin Thein, MD; Thura Win Htut, MBBS, MRCP, FRCPath	Outcomes and Health Services Research
13	Jiuhong Zha, PhD <i>AbbVie, Inc.</i>	First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia	Anjali Advani, MD; Olatoyosi Odenike, MD; Deepa Jeyakumar, MD; Raya Mawad, MD; Olga Frankfurt, MD; Jason G. Harb, PhD; Minh H. Dinh, MD; Brian Jonas, MD, PhD; Courtney D. DiNardo, MD	Clinical Oncology
14	Justin W. Shi, MD <i>Indiana University Melvin and Bren Simon Comprehensive Cancer Center NCCN Member Institution</i>	Exploring Epidermal Growth Factor Receptor (EGFR)-mutant Lung Squamous Cell Carcinoma (LSCC) in North America	Ahmad Karkash, MD; Weston He, MD; Mya Tran, PharmD; Misty Dawn Shields, MD, PhD; Julian A. Marin-Acevedo, MD	Clinical Oncology
15	Manu Prasad, MBA <i>BTech AstraZeneca</i>	Evaluating the Role of Social Determinants of Health (SDoH) in Predicting Surgical Delays and Impact on Healthcare Resources Utilization in Early-Stage NSCLC	Daniel Young, PhD; Tianyuan Hu, MPH; Atharv Sharma, BE; Arrvind Sunder, MS; Arindam Paul, Btech; Diganta Chowdhury, MEC	Best Practices in Implementation and Use of Clinical Practice Guidelines
16	Xiao Wang, MD <i>Yale Cancer Center/ Smilow Cancer Hospital NCCN Member Institution</i>	Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients with Advanced Non-Small Cell Lung Cancer	Do Lee, MPH; Szu-Chun Yang, MD, PhD; Yimeng Li, MPH; Pamela R. Soulos, MPH; Cary P. Gross, MD; Shi-Yi Wang, MD, PhD; Anne C. Chiang, MD, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
17	Carol-Ann Benn, MBBCh <i>Netcare Milpark Hospital</i>	Triage For Screening Programs: Colour Coding High-Risk Patient	Dominic van Loggereneberg; Charl van Loggereneberg, MBBCh, FCEM, MBA, DipPEC, DB; Bernado Rapoport, Mmed; Tanya Volschenk	Best Practices in Implementation and Use of Clinical Practice Guidelines
18	Vineet Polineni, DO <i>Jefferson Health</i>	Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample	Danielle C. Thor, DO, MAUB; Tony Elias, MS; Ben Brik, DO	Outcomes and Health Services Research
19	Marcus Curlin, BA <i>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine NCCN Member Institution</i>	Baseline Imaging in the Staging of Merkel Cell Carcinoma	N/A	Clinical Oncology
20	Nate Lear, MS, BS <i>ZS Associates</i>	Analyzing Real-World Impact of Delayed Neo-Adjuvant Treatment on Patient Outcomes in Gastric Cancer	Manu Prasad, MBA, Btech; Andrew Abdelmessih, BS; Darshan Gokalgandhi, B Tech; Atharv Sharma, BE; Prashant Poddar, MBA, MS; Ashutosh Naudiyal, B Tech	Outcomes and Health Services Research
21	Rama Nada, MD <i>Lincoln Medical and Mental Health Center</i>	How Mental Health and Substance Use Drive Cancer Disparities in Urban Communities	Eunhee Choi, MD; Abdullah Salahie, MD; Ho Yin Henry Chan, MD; Ruth Benites Llerena, MD; Alejandrina Cuello Ramirez, MD; Maria Albuja Altemirano, MD; Krishna Kishore Anne, MD; Lucia Boettner, MD; Ani Gvajaja, MD; Michael Imeh, MD; Gabriela Galicia Garcia, MD; Monika Ramzy, MD; Saad Alam, MD; Melissa Begolli, MD; Monica Reddy Muppidi, MD; Vidya Menon, MD	Outcomes and Health Services Research
22	Padma Sri Katikaneni, MD <i>University of Pittsburgh Medical Center Mercy</i>	Time Toxicity of Different Frontline Regimens in EGFR Mutated Non-small Cell Lung Cancer	Bowon Joung, MD; Won Jin Jeon, MD; Neha Agrawal, MD; Akshit Chitkara, MD; Rajat Thawani, MD	Outcomes and Health Services Research
23	Ellen McNeeley, MA <i>O'Neal Comprehensive Cancer Center at UAB NCCN Member Institution</i>	The State of Lung Cancer in Alabama	Elizabeth Dickson-Gavney, MS; Sanad Alhushki, MD; Sameer Deshmukh, MD; Ann Steagall, RN, BSN; Maya Khalil, MD; Yanis Boumber, MD, PhD; Aakash Desai, MD, MPH	Outcomes and Health Services Research

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
24	Malak Alharbi, MD Roswell Park Comprehensive Cancer Center NCCN Member Institution	Impact of Area Deprivation Index on Breast Cancer Survival and Rate of Germline Testing among Patients in Western New York	Jayasree Krishnan, MD; Arya Roy, MD; Archit Patel, MD; Riya Patel, MD; Ankita Kapoor, MD; Kayla Catalfamo, MA; Han Yau, PhD, MBBS; Kristopher Attwood, PhD; Angela Omilian, MD, PhD; Elizabeth Bouchard, MA, PhD; Song Yao, MD, PhD; Ellis Levine, MD; Tracey O'Connor, MD; Shipra Gandhi, MD	Epidemiology/Risks/Prevention
25	Irving Jesus Reyes, MD UC San Diego Moores Cancer Center NCCN Member Institution	Impact of Vaping on CDC42, RAC1, and SDC1 Gene Expression: Implications for Cancer Progression	Alexia Perryman; Laura Crotty Alexander	Correlative/Genomic
26	Maria Reyes-Matos, MD University of Virginia	Pre-menopausal Obesity Duration and Breast Cancer Risk in Women with Family History of Breast Malignancy	Asal Pilehvari, PhD; Roger Anderson, PhD	Epidemiology/Risks/Prevention
27	Chirag Shah, MD Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Member Institution	7-gene Biosignature Reclassified Women with DCIS Meeting NCCN Guideline (RTOG 9804-like) Low-risk Criteria as Molecular High Risk	Frank A. Vicini, MD; E. Connolly, MD; Rachel A. Rabinovitch, MD; Brian Czerniecki, MD; Gregory Bruce Mann, MBBS, PhD; Pat W. Whitworth, MD; Karuna Mittal, PhD; Steve Shivers, PhD; Troy Bremer, PhD	Clinical Oncology
28	Rishi Kumar Nanda, OMS-III Touro University Nevada College of Osteopathic Medicine	Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Health-Related Quality of Life (HRQOL) Events in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated with First-Line Immunochemotherapy	Hazem Aboaid, MD; Ramaditya Srinivasmurthy, OMS-IV; Kevin Nguyen, OMS-IV; Jason Ta, OMS-IV; Benjamin Tzer-Ming Chuang, MD; Yin Mon Myat, MD; Kyaw Zin Thein, MD	Outcomes and Health Services Research
29	Andre Bovell, MSc University of KwaZulu-Natal College of Health Sciences	Survival Analysis of Four Common Cancers in Antigua and Barbuda, 2017-2021: A Retrospective Study	Thendo Ramaliba, MSc; Adrian Rhudd, MBBS (UWI), DM (UWI) Urol, FRCSEd Urol; Jabulani Ncayiyana, PhD; Themba Ginindza, PhD	Epidemiology/Risks/Prevention
30	Julia Catini, PharmD, MBA Alexion	Cardiovascular Events in Patients Diagnosed with Light Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records	Pedro A. Lares, PhD; Shona Fang, PhD; Jennifer Evans, MPH; Jeffrey Thompson, PhD; Abhishek Gaur, PharmD; Brendon Staruk, MSc; Ankita Gupta, MSc; Richa Manwani, PhD	Epidemiology/Risks/Prevention
31	Harrison Nguyen, MD, MBA, MPH Houston Skin	The 31-GEP Identifies Patients with Early-stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-specific and Overall Mortality	Christine N. Bailey, MPH; Brian Martin, PhD; Sonia K. Morgan-Linnell, PhD; Valentina I. Petkov, MD, MPH; Michael Tassavor, MD, MS	Correlative/Genomic
32	Skye O. Dougan, MPH Moffitt Cancer Center NCCN Member Institution	Utilizing Augmented Reality as an Adjunct for Smoking Cessation: Trial in Progress	Helen C. Yates, MPH; Marilyn Horta, PhD; Karen O. Brandon, PhD; Madison Rivera, BS; Halle R. Smith, BS; Ursula Martinez, PhD; Steven K. Sutton, PhD; Damon J. Vidrine, DrPH; Lee H. Ritterband, PhD; Kara P. Wiseman, PhD; Katrina A. Vickerman, PhD; Ranjita Poudel, PhD; Min-Jeong Yang, PhD; Thomas H. Brandon, PhD; Christine Vinci, PhD	Trials in Progress
33	Yenong Cao, MD, PhD Tufts Medical Center Cancer Center	EPIC Patient Portal Functionality: An Equity Analysis in Vulnerable Cancer Patients	Marie Noelle Bate Baiyee, PharmD, RPH; Johnson Ching, PharmD, CSP; Rachel Murphy-Banks, MA; Fengqing Wang, BS; Antonia Maloney, BS, RN ,OCN; Angie Mae Rodday, PhD MS; Susan K. Parsons, MD, MRP	Outcomes and Health Services Research
34	Muhammad Awidi, MD Roswell Park Comprehensive Cancer Center NCCN Member Institution	Impact of Bone Metastasis on Survival in Gastric and Gastroesophageal Junction Tumors	Muntaser Al Zyouid; Osama M. Younis; Sarbajit Mukherjee, MD	Clinical Oncology
35	Ramaditya Srinivasmurthy, OMS-IV Touro University Nevada College of Osteopathic Medicine	Incidence of Hematologic Adverse Events in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated with Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials	Hazem Aboaid, MD; Abbas Hussain, MD; Riccesha Hattin, DO; Savannah Schauer, MS-III; Tal Schlesinger, MS-III; Rory Twells, MS-III; Karl Aharonian, MS-III; Ryan Parto, MD; Rodd Rahmani, MD; Chalette Lambert-Swainston, MD; Daniel Thomas Jones, OMS-IV; Kyaw Zin Thein, MD	Outcomes and Health Services Research
36	Grace K. Lee, BA University of South Florida Morsani College of Medicine	Improving Quality Outcomes through a Hospitalist-Driven Malignant Hematology Service	Steven Benyahia, BA; Mish Syed, MD; Hardik Thakkar, PA-C; Richard Reich, PhD; James Lochner, MS, MBA; Leidy Isenalumhe, MD; Timothy Hembree, DO, PhD; Neha Verma, MD; Enas Abdallah, MD	Quality Improvement
37	Betty Ben Dor, BS Harvard School of Dental Medicine	A Comparison of Demographic Characteristics of Individuals with Head and Neck Cancer (HNC) Among Multiple Datasets	Elizabeth Alpert, DDS, MPH; Brooke R. Warren, MD; Sathesh Kumar Poolakkad Sankaran, DDS, MDS, MSc, MMSc; Stephen T. Sonis, DMD, DMSc; Alessandro Villa, DDS, MPH, PhD	Epidemiology/Risks/Prevention

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
38	Pratyusha Vadagam, MS <i>Janssen Scientific Affairs, LLC</i>	Patient Preferences and Willingness to Accept Trade-offs for a Favorable Treatment Response Among Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer	Lisa Dwyer Orr, MPH; Julie Vanderpoel, PharmD, MPA; Margaret Yung, PharmD; Kathleen L. Deering, PharmD; Victoria Kulbokas, PharmD	Outcomes and Health Services Research
39	Sally Werner, RN, BSN, MSHA <i>Cancer Support Community</i>	Patient Perceptions of Artificial Intelligence in Healthcare: Findings from the Cancer Experience Registry	Abigail Newell, PhD; Sabrina Pink, PhD	Bioinformatics/Information Technology Sciences
40	Ryne Ramaker, MD, PhD <i>Duke Cancer Institute</i> NCCN Member Institution	Identifying Barriers to Comprehensive Genomic Profiling for Patients in Academic and Community Oncology Centers	Parker Mathews, MD; Jennifer Owen, BA; Ashley Moyer, BS; Bennett Caughey, MD; Nicholas Mayne, MD; Linda Sutton, MD; Hui Chen, MD; John Strickler, MD	Quality Improvement
41	Peter Schiemann, PhD <i>Ymmunonbio</i>	Design of Novel Antibody Drug Conjugates using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology	Michel Janicot, PhD; Gunther Wennemuth, MD; Mykola Lyndin, MD; Janine Moyer, PhD	Pre-Clinical Oncology
42	Rozee Junhan Liu, MSc <i>Eviviz</i>	Real-time Clinical Trial Data Library in Non-small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality with a Finetuned Large Language Model (LLM)	Anna Forsythe, MBA, MSc, PharmD; Jessica Martin Rege, PhD; Peter Kaufman, MD	Bioinformatics/Information Technology Sciences
43	Brittany Faye Sears, PhD, MSPH, LCGC <i>Tampa General Hospital</i>	Digital Tools to Transform NCCN Guidelines into Germline Genetic Counseling	Megan Clement, BA	Best Practices in Implementation and Use of Clinical Practice Guidelines
44	Jonas M. Congelli, RPh <i>Hematology Oncology Associates PC</i>	Improving Patient Access and Adherence: The Role of an Electronic Health Record (EHR)-Embedded Clinical Decision Support (CDS) Tool in Specialty Drug Management	Anna Bolha, MPAS, PA-C; Rebecca Maniago, PharmD, BCOP; Mandi Vena, PharmD, BCOP; Marcello Riccottoni, MA, BS; Maneet Kaur, PhD, MPH; Stephen Speicher, MD, MS	Best Practices in Implementation and Use of Clinical Practice Guidelines
45	Sai Gautham Kanagala, MBBS <i>New York City Health and Hospitals Metropolitan</i>	Prevalence of Cannabis Use Disorders Among Hospitalized Elderly Cancer Survivors: Nationwide Trends and Disparities (2016-2020)	Neha Singh, MBBS; Laxman Yashwant Byreddi, MBBS, MD; Thanmai Reddy Thugu, MD; Muskan Jain, MBBS; Neeharika John Madhavaram, MBBS; Diksha Sanjana Pasnoor, MBBS; Sonali Dash; Ahmad Alhomaïd, MD; Akhil Jain, MD; Rupak Desai, MBBS;	Clinical Oncology
46	Vishnu Prasath, MD, MS <i>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</i> NCCN Member Institution	Treatment Patterns and Prognosis of Patients with HER2-Negative Early Breast Cancer and Germline Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2	Andrea Riner, MD; Joanne Kim, PhD; Akia Clark, BS; Brandon Slover, SMB; Bridget Oppong, MD, MPH, FACS; Robert Wesolowski, MD; Kai Johnson, MD; Sagar Sardesai, MD	Outcomes and Health Services Research
47	Patxys Taveras, MD <i>St. Barnabas Hospital</i>	Racial Disparities in Palliative Care (PC) Access Among Patients with Malignant Brain Tumors (MBT): A Retrospective Analysis Using the National Inpatient Sample (2014-2020)	Nehemias Antonio Guevara Rodriguez, MD; Noemy Coreas, MD; Esmirna Perez, MD; Asad Ur Rehman, MD; Binay Kumar Panjiyar, MD; Lina Toledo Franco, MD; Asha Ricciuti, MD	Outcomes and Health Services Research
48	Pat Whitworth, MD <i>PreludeDx</i>	The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ	Rachel Rabinovitch, MD; Pat Borgen, MD; Anna Daily, PhD; Steve Shivers, PhD; Troy Bremer, PhD	Trials in Progress
49	Ajeet Gajra, MD, MBBS, FACP <i>Hematology Oncology Associates</i>	Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy with or without Trilaciclib	Peter Reeves, PhD; Susan O'Brien, MS; Anna Carey; Michelle Moore, RPh; Huan Huang, PhD	Outcomes and Health Services Research
50	Ali Mohtashami, MBBS, MMed, MPH, FRACS <i>Royal North Shore Hospital</i>	The Role of Trans-arterial Angioembolization in the Management of Lower Gastrointestinal Bleeding: A Metaanalysis	Krishna Kotecha, MBBS, Mphil	Best Practices in Implementation and Use of Clinical Practice Guidelines
51	Abdu Mohammed, MD <i>Trinity Health System</i>	The Epidemiology and Clinical Outcomes of Lung Cancer Patients with Hypercalcemia: Evidence from a National Inpatient Database	Adamsged Isac Gebremedhen, MD; Yifang Song, MD, PhD; M. Pervaiz Rahman, MD; Kevin Dell, MD, PhD; Muhammed Y. Jumani, MD; Love Kumar, MD	Outcomes and Health Services Research
52	Carla Herman <i>McGill University</i>	Why Don't They Want to Wear Sunscreen? Quantifying Anti-Sunscreen Messaging on TikTok	Nathalie Harb, MDCM Candidate; Meghri Ghazarian, DEC; Eric Belzile, BSc; Nina Morena, MA; Ari N. Meguerditchian, MD, MSc, FRCS, FACS	Bioinformatics/Information Technology Sciences

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
53	Chahat Rana, BS <i>UT Southwestern Simmons Comprehensive Cancer Center NCCN Member Institution</i>	The Use of Self Mixed Morphine Gel 0.125% for Topical Pain Control in Painful Cancer Lesion	Sean Hutchinson, MD; Nicholas Lorusso, PhD; Kelley Newcomer, MD	Quality Improvement
55	Shammas Bajwa, MD <i>Oklahoma University Medical Center</i>	Primary Cardiac Soft Tissue Sarcoma: A Retrospective Analysis	Hassan Ali, MD, MBBS; Usman Itoo, MD; Muhammad Aameish, MD; Aisha Abdul Sattar, MD; Rabia Naseem, MD; Rajesh Thirumaran, MD	Epidemiology/Risks/Prevention
56	Kabir Grewal, MD <i>Baylor College of Medicine</i>	Lenvatinib with Pembrolizumab in Advanced Biliary Tract Cancer	Shubham Pant, MD; Ian Hu, MD, PhD; Madhulika Eluri, MD; Amy An, MD; Victoria Higbie, MD; Ryan Huey, MD; Ahmed Kasab, MD; Milind Javle, MD; Sunyoung Lee, MD, PhD	Clinical Oncology
57	Avery Zona Wright, BS <i>Wake Forest University School of Medicine</i>	Elevating Cancer Care: Launching a Comprehensive Nutrition and Wellness Program at a Multisite Cancer Center	Michele L. Szafranski, MS, RDN, CSO, LDN; Patricia M. Fogarty, MS, RDN, LDN; Aynur Aktas, MD; Declan Walsh, MD, MSc; Kunal C. Kadakia, MD	Outcomes and Health Services Research
58	Zhuoqun Lin, MS <i>Women's Hospital School of Medicine Zhejiang University</i>	HIF-1α Inhibitor ACF Synergizes with PARP Inhibitors Through the Exacerbation of Transcription-replication Conflicts in Ovarian Cancer	Jiaxin Gu; Dongxiao Hu; Tao Zhang; Ziyu Xing, Ms; Lingfang Wang; Xiaodong Cheng	Pre-Clinical Oncology
59	Niyas Amir, MD <i>Regional Cancer Centre Thiruvananthapuram</i>	MicroRNA Expression Profiles in Non-small Cell Lung Cancer Related Pleural Effusion and its Prognostic Significance in Treatment Response and Survival Outcome	Anoop Tm, MD; Preethi Sara George, MD; Lakshmi S., PhD	Correlative/Genomic
60	Muntaser Al Zyoud <i>The University of Jordan</i>	Immune Checkpoint Inhibitor Therapy and the Risk of Second Primary Malignancies in Melanoma and Lung Cancer Patients	Osama M. Younis; Muhammad Awidi, MD	Clinical Oncology
61	Pritesh S. Karia, PhD, MPH <i>Oncology Outcomes Research, AstraZeneca</i>	Real-world Effectiveness of First-line Osimertinib for Patients in the US with Epidermal Growth Factor Receptor-mutated Advanced Non-small Cell Lung Cancer who were Eligible for Medicare	Yan Kwan Lau, PhD, MPH; Darren Thomas, PhD; Rachel Salomonsen, PhD, MPH; Rahul Shenolikar, PhD	Outcomes and Health Services Research
62	Sumit Verma, BPharm, MS <i>Incyte Corporation</i>	Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary	Sunyoung Lee, MD; Mike Blecker, PharmD; Alejandro Hughes, MPH; Nicole M. Engel-Nitz, PhD; Shreekant Parasuraman, BPharm, PhD; Milind Javle, MD	Outcomes and Health Services Research
63	Lai Yuting <i>Yat-Sen Memorial Hospital</i>	Development and Validation of a Prediction Model for Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy in Patients with Ovarian Cancer	Yanan Lu; Dan Xie; Hui Li, MD; Dongyan Wang, MD Yichun Xing, MD; Miaofang Wu, MD; Jing Li, MD	Clinical Oncology
64	Apple Liu, MD <i>Morehouse School of Medicine</i>	MGUS and SMM Patients Specialist Follow up and Laboratory Surveillance Rates in a Community Safety Net Hospital Setting	Kapil Chandora, MD; Hafsa Gundroo, MD; Benson Arnett, MD; Alexis Fields, MD; Krystal Mathew, MD	Clinical Oncology
65	Heather M. Johnson, MPA <i>The University of Texas MD Anderson Cancer Center NCCN Member Institution</i>	Increasing Access and Reducing Barriers to Colorectal Cancer Screening (CRCS) Among Low-Income and/or Uninsured Adults Ages 45 to 75 in Texas Through a FITfirst Approach: Project 80%	Sonia Gilmore, PhD; Diane Benson, BA; Carolyn Bernard, BA, CPHIMS; Lewis E. Foxhall, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
66	Emily Fogarty, PhD <i>Ignite Proteomics</i>	MHC II More Effectively Predicts Response to Pembrolizumab than PD-L1 in HER2 Negative Patients	Brian Corgiat, PhD; Kayla Sparks, PhD; Chris Arnell, MBA; Emanuel Petricoin, PhD; Justin Davis, PhD; Claudius Mueller, PhD	Correlative/Genomic
67	Diksha Sanjana Pasnoor, MBBS <i>Kamineni Academy of Medical Sciences and Research Centre</i>	Prognostic Role of Pre-Transplant EASIX on Non-Relapse Mortality and Overall Survival in Allogeneic Stem Cell Transplantation: A Meta-Analysis	Rishabh Arun Vashisht, MBBS; Mohit Mirchandani, MD; Nancy Ganatra, MD; Beenish Najam, MBBS; Akhil Jain, MD; Rupak Desai, MBBS	Clinical Oncology
68	Noreen F. Khan, BS <i>University of Michigan Rogel Cancer Center NCCN Member Institution</i>	Examining Molecular Features of Rare Brain Metastases Patient-Derived Xenograft Models	Derek Nancarrow, PhD; Peter Ulintz, PhD; Tusharika Rastogi, MS; Habib Serhan, BS; Xu Cheng, MBBS; Liwei Bao, MD; Aaron Udager, MD, PhD; Matthew Soellner, PhD; Edwin Nieblas-Bedolla, MD, MPH; Jason Heth, MD; Nathan Merrill, PhD; Sofia D. Merajver, MD, PhD; Aki Morikawa, MD, PhD	Pre-Clinical Oncology

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
69	Vicky Makker, MD Memorial Sloan Kettering Cancer Center NCCN Member Institution	Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated with Anti-PD-(L)1 Immunotherapy	Ramez Eskander, MD; Jung-Yun Lee, MD, PhD; Mansoor Mirza, MD; Domenica Lorusso, MD, PhD; Helen Mackay, MD; Isabelle Ray-Coquard, MD, PhD; Ana Oaknin, MD; Antonio Gonzalez-Martin, MD; Kosei Hasegawa, MD, PhD; Bradley Corr, MD; Xiaohua Wu, PhD; Alexandra Leary, MD, PhD; Tianle Hu, PhD; Lea Dutta, PharmD; Chinyere Okpara, PhD; Jodi McKenzie, PhD	Trials in Progress
70	Oboseh John Ogedegbe, MD Trinity Health Ann Arbor Hospital	Second Primary Malignancy in Multiple Myeloma Survivors: A Population-Based Retrospective Cohort Study	Olanipekun Lanny Ntukidem, MD; Sakshi Bai, MD; Ahmed Bashir Sukhera, MD; Stanley Ntow Atencah, MD	Epidemiology/Risks/Prevention
71	Teodora Kuzmanovic, BA Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Member Institution	Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients- Testing and Referral Guidelines	Maedeh Zoakei Nikoo, MD; Sindhusa Veereballi, MD; Ahmad Safdar, MD; Sakthi S. Prakash, MD; Emmett Samsa, BS; David Bosler, MD; Halle C. F. Moore, MD; Jame Abraham, MD; Jessica Geiger, MD; Aaron T. Gerds, MD; Anjali S. Advani, MD; Sudipto Mukherjee, MD, MPH; John C. Molina, MD; Sophia Balderman, MD; Moadh Mustafa Ali, MD, MPH; Jaroslaw P. Maciejewski, MD, PhD; Akriti Jain, MD; Hetty Carraway, MD, MBA; Bhumika Patel, MD; Rohit Moudgil, MD, PhD; Abhay Singh, MD, MPH	Epidemiology/Risks/Prevention
72	Allison Lam, PharmD Long Beach Medical Center	A Case Study of Implementation of Clinical Decision Support Tools in the Expansion of Use of Bispecific T-Cell Engager (BiTE) therapies in a Community Hospital System	Milan Sheth, MD; Angela Yencer, MSN; Jeanette Prado, MSN	Best Practices in Implementation and Use of Clinical Practice Guidelines
73	Parth Sharma, MD University of Missouri-Kansas City School of Medicine	Risk of Trastuzumab Deruxtecan (T-DXd) Associated Interstitial Lung Disease (ILD)/ Pneumonitis: A Real-world Population-based Propensity-matched Analysis	Piyush Nathani, MD; Rohit Nathani, MD; Anuj Shrestha, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
74	Sofia Ines Cuello The University of Tampa College of Natural and Health Sciences	Investigating Mechanisms of Antioxidant Treatment on Drug Resistant Breast Cancer	Kimberly Dobrinski, PhD	Clinical Oncology
75	Rosaleen Duggan Bloom, PhD, MS, BSN, APRN Texas A&M University	Potential Factors Impacting Adherence with National Comprehensive Cancer Network Radiation Therapy Guidelines for Early-stage Breast Cancer	Wen Hsin Chen, MSc, BSN, RN; Jane Nelson Bolin, PhD, JD, BSN, RN	Outcomes and Health Services Research
76	Anamika Chaudhuri, PhD Dana-Farber/Brigham and Women's Cancer Center Mass General Cancer Center NCCN Member Institution	Evaluating Implementation of Advanced Provider Driven Comprehensive Management Program to Support Patients with Immune-oncology Toxicity	Julia S. Pimkina, MD, PhD	Quality Improvement
77	Minh Anh Le, MD University of Central Florida	Statin Use and Reduced Incidence of Colorectal Cancer in Veterans: A Nested Case-Control Study	Alfredo E. Palomino Abella, MD; Richard Henriquez, MD; Ishak Mansi, MD	Epidemiology/Risks/Prevention
78	Sarah Blythe, BSN, RN Advocate Aurora Illinois Masonic Medical Center	Developing an Artificial Intelligence Tool for Personalized Breast Cancer Treatment Plans based on the NCCN Guidelines	Iqtidar Mansoor, MD; Abdul Moid Mohammed, MS, CS	Best Practices in Implementation and Use of Clinical Practice Guidelines
79	John Leonard Fox, MD Illumina Inc.	Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers	Sugganth Daniel, MD, PhD; Manavi Abrol, PhD	Correlative/Genomic
80	Sivaguha Yadunath Prabhakaran, MD Mercy Fitzgerald Hospital	Brenner Tumor Prognostication Based on Race and Laterality	Hassan Ali, MD; Rajesh Thirumaran, MD; Krishna Desai, MD	Epidemiology/Risks/Prevention
81	Sarah Eidbo, MD Albert Einstein Medical Center	Long-term Outcomes in Patients with Tumor Lysis Syndrome and Comorbid Gout: A Propensity-Matched Study from the Global Federated Health Research Network	Nanuka Tsibadze, MD; Diego Lema, MD, PhD; Justin Lam, MD; Fabian Rodriguez, MD	Outcomes and Health Services Research
82	Sydney Freiberg, BS University of Wisconsin Carbone Cancer Center NCCN Member Institution	Acceptability, Facilitators, and Barriers to the Implementation of Screening and Brief Intervention for Alcohol Counseling in the Oncology Setting	Noelle LoConte, MD	Quality Improvement
83	Abhishek Gugliani, MBBS, MS, DNB Amrita Institute of Medical Sciences	Sentinel Node Biopsy Versus Elective Neck Dissection for Early Stage Tongue Cancers: Comparing Morbidity, Functional and Quality of Life Outcomes	Litta Justine, MBBS, MS; Lakshmi Menon, MBBS, MS, MCh; Tejal Patel, MBBS, MS, MCh; Deepak Balasubramanian, MBBS, MS, DNB, MCh; Subramania Iyer, MBBS, MS, MCh, FRCS; Krishnakumar Thankappan, MBBS, MS, DNB, MCh	Outcomes and Health Services Research

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
84	Jaison Lawrence Alexander Santhi, MD <i>Mercy Fitzgerald Hospital</i>	Epidemiology of Giant Cell Glioblastoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis	Hassan Ali, MD, MBBS; Shammass Bajwa, MD; Satya Durugu, MD; Sivaguha Yadunath Prabhakaran, MD; Hafiz Muhammad Ajmal Saleem, MD; Elizaveta Bodrova, MD; Rajesh Thirumaran, MD	Epidemiology/Risks/Prevention
85	Dominic van Loggerenberg <i>Netcare Milpark Hospital</i>	AI Tracking Multidisciplinary Decision Making: Enabling A Regional Support Tool	Charl van Loggerenberg, MBBCh, FCEM, MBA; Carol-Ann Benn, MBBCh; Tanya Volschenk	Bioinformatics/Information Technology Sciences
86	Govind Warriar, MD, MPH <i>Johns Hopkins Kimmel Cancer Center</i> NCCN Member Institution	Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients with Melanoma Access Multidisciplinary Cutaneous Oncology Care	Shannon Kehrl, BA; Renee Ofori, BS; Hao Wang, PhD; Daniel Matiaudes, BA; Ivis Alfaro, BA; Naru Sato, BA; James Huang, MS; Cheryl Stratos, MS; Lara Yuan, BA; Adrian Dobs, MD, MHS; Rose Wang, MBA, MSCS; Evan Jacob Lipson, MD	Bioinformatics/Information Technology Sciences
88	Misbahuddin Syed, MD <i>Moffitt Cancer Center</i> NCCN Member Institution	Demonstrating Value of a Shared Management Approach in the Care of Surgical Oncology Patients at an Academic Cancer Center	Reurita Deam, MSN, MBA, RN; Timothy Hembree, DO, PhD	Quality Improvement
89	Laura Hanisch, PsyD <i>National Comprehensive Cancer Network</i>	Do Oncology Patients Want to Know Both Generic and Brand Drug Names?	Erin Vidic, MA; Tanya Fischer, MEd, MS; Tim Rinehart, MS; Patrick K. Delaney, BA; Crystal S. Denlinger, MD; Dorothy Shead, MS	Quality Improvement
90	Osama M. Younis <i>The University of Jordan</i>	Hereditary Porphyria and the Risk of Hematological and Solid Malignancies: A Retrospective Cohort Study	Muntaser Al Zyoud; Muhammad Awidi, MD	Clinical Oncology
92	Anjali Sibley, MD, MPH <i>Stanford Cancer Institute</i> NCCN Member Institution	What Patients Anticipate About Working Out with Cancer: Qualitative Survey Results	Simran Lauers, BS; Khay Asuncion, BS; Jessica Liang, MSN; Julianna Giarrusso, MS; Dorely Bernardez; Laura Holdsworth, PhD; Kavitha Ramchandran, MD	Quality Improvement
93	Amanda Watson, BS <i>Lymphoma Coalition</i>	Mapping Patient Reported Side-effect Incidence to Degradation of Health-related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia - A Study from the Lymphoma Coalition's 2024 Global Patient Survey on Lymphomas & CLL	Steve E. Kalloger, MSc; Shawn Sajkowski, BS; Natacha Bolaños, BN; Lorna Warwick, BEd	Outcomes and Health Services Research
94	Rajbir Pahil, MD <i>Cape Breton Cancer Center</i>	The Effectiveness of Implementing a Community-Based Lung Clinic in Rural Community Cancer Center	Enam A. Alsayheen, PhD; Danial G. French, MD; Alexander Ednie, MD; Aneil Mujoomdar, MD; Madelaine Plourde, MD; Valerie Nugent, RN; Kwamena Beecham, MD; Alison Wallace, MD; Yoana Fuentes, BSc; Sarah Gillis, BNSc; Godson Johnson, BSc	Outcomes and Health Services Research
95	Halle R. Smith, BA <i>Moffitt Cancer Center</i> NCCN Member Institution	Linking COVID-related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients	Marilyn Horta, PhD; Skye O. Dougan, MPH; Sierra J. Washington, MPH; Helen C. Yates, MPH; Joseph Pidala, MD, PhD; Maija Reblin, PhD; Heather Jim, PhD; Steven K. Sutton, PhD; Christine Vinci, PhD	Outcomes and Health Services Research
96	Adrienne M. Gilligan, PhD <i>Eli Lilly and Company</i>	Real-World Study Demonstrates Lack of Biomarker-driven Care in First-Line Treatment for Advanced/Metastatic Non-Small Cell Lung Cancer that Received Next-Generation Sequencing Testing	Melina E. Marmarelis, MD, MSCE; Tomoko Sugihara, MS; Shen Zheng, PhD; Tyler Marquart, PhD; Sam Whipple, MPH; Naleen Raj Bhandari, MS, PhD; Charu Aggarwal, MD, MPH	Outcomes and Health Services Research
97	Kailash Kumar Mittal, MD <i>Uttar Pradesh University of Medical Sciences</i>	Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach with Flattening Filter-Free vs. Filtered Beams	Atul Mishra, PhD; Sumanta Manna, DRP; Neha Yadav, PhD; Sharad Singh, MD	Quality Improvement
98	Nur Rahman, MD <i>Bridgeport Hospital</i>	Single Dose Nivolumab and Ipilimumab Treatment Causing Complete and Durable Response in Extensive Stage - Small Cell Lung Cancer Complicated by Severe Sensory Autoimmune Neuropathy	Aaron Charles Lobo, MD; Nicholas Blondin, MD; Neal Fischbach, MD	Clinical Oncology
99	Feifei Song Zhejiang <i>University School of Medicine Women's Hospital</i>	Effects and Mechanisms of CD16+/-NK Cells on Ovarian Malignant Tumor Cells Platinum-based Drug Responsiveness in Tumor Microenvironment	Xiaodong Cheng, MD	Clinical Oncology
100	Michael Vredenburg, PhD <i>Sobi Inc.</i>	Pacritinib in Patients with Intermediate-1 Risk Myelofibrosis: Outcomes from Post-hoc Analysis of Two Phase 3 Studies	Pankit Vachhani, MD; Nikolai Podoltsev, MD, PhD; Ashwin Kishtagari, MD; Purvi Suthar, PharmD, RPh; Karisse Roman-Torres, PhD; Aaron Gerds, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
101	Bindu Kuriacose, MSN, RN The University of Texas MD Anderson Cancer Center NCCN Member Institution	Implementing a No-Cost Strategy to Minimize Blood Product Waste in a High-Volume Hematology/Oncology Intermediate Care Unit	Annie Abraham, MSN, RN, CNL, OCN; Neicole James, MSN, RN, OCN	Best Practices in Implementation and Use of Clinical Practice Guidelines
102	Todd William Mudd, MD O'Neal Comprehensive Cancer Center at UAB NCCN Member Institution	Real-World Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Insights from a Single Center in the Deep South	Faris A. Abby, MD; Darryl Outlaw, MD; Mehmet Akce, MD; Bassel El-Rayes, MD; Midhun Malla, MD; Qasim S. Hussaini, MD; Garima Gupta, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
103	Richard Zuniga, MD NY Cancer and Blood Specialists	The Impact of ChemoMouthpiece Device on Analgesic Use for Oral Pain in a Randomized, Prospective, Multi-Center Trial for Patients Undergoing Stomatotoxic Chemotherapy	N/A	Clinical Oncology
104	Bea Bakshi, MBBS, MRCGP, BSc Memorial Sloan Kettering Cancer Center NCCN Member Institution	Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment	Sana Raoof, MD, PhD; Seema Dadhania, MBBS, MRCP; Tushar Patel, MB, ChB; Brian Herrick, MD; Miles Payling, MBBS, BSc, MRCP	Bioinformatics/Information Technology Sciences
105	Honghui Huang, PhD Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital	A Multicenter, Randomized, Controlled, Non-inferiority Study of Nalumsobart Compared With Denosumab in the Treatment of Bone Disease in Patients with Multiple Myeloma	Fei Li, PhD; Yan Xu, PhD; Wenming Chen, PhD; Guangxun Gao, PhD; Zhongjun Xia, MD; Xiaobing Huang, PhD; Jun Luo, PhD; Xiaoling Guo, PhD; Chunrui Li, PhD; Chunyan Sun, PhD; Baijun Fang, PhD; Fengyan Jin, PhD; Yongqian Jia, PhD; Shuhao Mei, MD; Juan Du, PhD; Rong Zhan, BD; Zhen Cai, PhD; Luqun Wang, PhD; Hongfeng Ge, MD; Xiuhua Han, MD; Jian Hou, PhD	Clinical Oncology
106	Nisheem Pokharel, MD St. Francis Medical Center	Therapy-induced Acute Myeloid Leukemia in Multiple Myeloma Patients: Database Analysis of Risk, Overall Survival and Prognostic Factors	Pravash Budhathoki, MD; Navin Ramlal, MD; Nehemias Guevara-Rodriguez, MD; Elina Shrestha, MD	Epidemiology/Risks/Prevention
107	Elizabeth Fleagle, PsyD University of Colorado Cancer Center NCCN Member Institution	Utilizing Patient and Provider Perspectives in Psycho-Oncology Program Development and Quality Improvement	Erin Baurle, PsyD	Quality Improvement
108	Kriti Dhamija, MD Allegheny Health Network	Survival Analysis for Early Onset and Very Early Onset Colon Cancer Using National Cancer Database (NCDB) 2004-2021	Kojo Frimpong Awuah, MD; Dulabh Monga, MD; Rodney Wegner, MD; Yue Yin, PhD	Outcomes and Health Services Research
109	Kelly Brassil, PhD, MSN, MAR, BASW Quest Diagnostics Inc.	Comprehensive Outcomes for After Cancer Health (COACH) Study: 2024 Trial in Progress Updates	Barbara Halpenny, MA, MSW; Elizabeth Arthur, PhD, RN; Maria Chang Swartz, PhD, MPH; Abbey Kaler, MSW, RN; Jessica Krok-Schoen, PhD; Robin Lally, PhD, RN; Jennifer Loftis, DNP, RN; Leorey Saligan, PhD, RN; Rachael Schmidt, DNP; Angela Starkweather, PhD, RN; Alexi Wright, MD, MPH; Meagan Whisenant, PhD, RN; Sarah Alzahid, MSN, BSN; Betty Arceneaux, CMA; Lauren Ashley Anderson, MSN; Jerry Armah, BSN; Kristen Fessele, PhD, RN; Laura Flora, MCW; Alyssa Garcia, BS; Anneliese Gonzalez, MD; Michael Harrison, MPH; Kaukab Jafry, MD, MBBS; Rebecca Johnson-Beller, PhD; Ginny Kirklin, MPH; Arianna Mohan, BA; Darcy Ponce, BS; Whitney Posada, BA; Elham Samami, BSN, RN, MS; Grace Smith, MD, PhD, MPH; Gisele Tlusty, PhD; Martha Thompson, BCM; Inga Van Wieren, BA; Gloria Yang, BA; Marilyn Hammer, PhD, RN	Trials in Progress
110	Oboseh John Ogedegbe, MD Trinity Health Ann Arbor Hospital	Sociodemographic Disparities in Survival Outcomes Among Adolescent and Young Adult Patients with Lung Cancer: Insights from a SEER Database Analysis	Olanipekun Lanny Ntukidem, MD; Ayobami Gbenga Olafimihan, MD; Sakshi Bai, MD; Inimfon Jackson, MD, PhD, MPH	Outcomes and Health Services Research
112	Fiqe Khan, MD Brooklyn Hospital Center	The Changing Landscape of Venous Thromboembolism in Breast Cancer: Trends Over The Years 2016-2020	Jayalekshmi Jayakumar, MD; Manasa Gijnupalli, MD; Davin Turku, MD; Surbhi Singh, MD; Arya Mariam Roy, MD	Epidemiology/Risks/Prevention
113	Zunairah Shah, MD Roswell Park Comprehensive Cancer Center NCCN Member Institution	Investigating Socioeconomic and Racial Disparities in Pathologic Response and Survival Outcomes in Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy: Insights from the National Cancer Database	Malak Alharbi, MD; Mengyu Fang, NA; Han Yu; Shipra Gandhi, MD	Outcomes and Health Services Research

General Poster Sessions | Session I | Friday, March 28 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
114	Amber Gilbert, DNP, AOCNP, APRN Moffitt Cancer Center NCCN Member Institution	Cultivating a Nocturnal Culture of Patient Safety in a Newly Established Surgical Oncology Hospital by Enhancing Confidence	Adam Winkler, MD; Kenneth Snell, MD	Quality Improvement
115	Jivesh Sharma, MD Medical City Dallas Hospital	Advancing Clinical Decision-Making: Evaluating AI-Driven Support with Cancer Companion GPT against Criterion™ Insights	Rena J Vanzo, CGC, MBA; Neal Sharma, MD; Tawanna St. Lewis, CGC; Rekha Sharma, BS; Cheryl Reeves, CGC; Poonam Sharma, PhD; John Tan, MD, PhD; Pranav Mukund, BS	Bioinformatics/Information Technology Sciences
116	Shammas Bajwa, MD Oklahoma University Medical Center	Epidemiology of Olfactory Neuroblastoma: A SEER Stat Review	Hassan Ali, MD, MBBS; Krishna Desai, MD; Muhammad Aameish, MD; Usman Itoo, MD; Rajesh Thirumaran, MD	Epidemiology/Risks/Prevention
117	Daniel Thomas Jones, OMS-IV Touro University Nevada College of Osteopathic Medicine	Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated with Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials	Abbas Hussain, MD; Hazem Aboaid, MD; Riccesha Hattin, DO; Savannah Schauer, MS-III; Tal Schlesinger, MS-III; Rory Twells, MS-III; Karl Aharonian, MS-III; Ryan Parto, MD; Rodd Rahmani, MD; Chalette Lambert-Swainston, MD; Ramaditya Srinivasmurthy, OMS-IV; Kyaw Zin Thein, MD	Outcomes and Health Services Research
118	Hazem Aboaid, MD University of Nevada Las Vegas Kirk Kerkorian School of Medicine	Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients with Relapsed/Refractory Multiple Myeloma Treated with Belantamab Mafodotin	Riccesha Hattin, DO; Abbas Hussain, MD; Savannah Schauer, MS-III; Tal Schlesinger, MS-III; Rory Twells, MS-III; Karl Aharonian, MS-III; Ryan Parto, MD; Rodd Rahmani, MD; Chalette Lambert-Swainston, MD; Daniel Thomas Jones, OMS-IV; Ramaditya Srinivasmurthy, OMS-IV; Kyaw Zin Thein, MD; Thura Win Htut, MBBS, MRCP, FRCPath	Outcomes and Health Services Research
119	Zorica Novakovic, MD University Clinical Centre of the Republic of Srpska	Rare Tumors of the Larynx	N/A	Clinical Oncology
120	Victoria McClosky, BSN The University of Texas MD Anderson Cancer Center NCCN Member Institution	Enhancing Communication Through Interprofessional Goal Concordant Care Training	Enefe Queen Adaji, MHA; Gary Martinez, DNP, MSN-Ed	Quality Improvement
121	Ahmad Karkash, MD The University of Texas MD Anderson Cancer Center NCCN Member Institution	Impact of Social Determinants of Health on Lung Cancer Screening and Small Cell Lung Cancer Outcomes in a County Hospital	Weston He, MD; Mya Tran, PharmD; Julian A. Marin-Acevedo, MD; Misty Dawn Shields, MD, PhD	Outcomes and Health Services Research
122	Ana Flores Pimentel, BS UC San Diego Moores Cancer Center NCCN Member Institution	Improving Germline Testing in At-Risk Patients With Prostate Cancer	Juan Javier-DesLoges, MD; Yu-Wei Chen, MD; Yasoda Satpathy, BS; James Michael Randall, MD; Christopher Kane, MD Lisa Madlensky, PhD; Matthew Savage, PhD; Samuel Pena, BS; Tyler Stewart, MD; Aditya Bagrodia, MD; Rana McKay, MD	Clinical Oncology
123	Ania Khachikian UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution	The RKIP-HER2 Axis in Breast Cancer and Role in Immune Evasion	Mai Ho; Benjamin Bonavida, PhD	Pre-Clinical Oncology
124	Caroline Horne, DO Carolinas Medical Center	Rare Case of Immune Checkpoint Inhibitor Induced Myocarditis and Myositis: Diagnosis and Management	N/A	Case Reports
125	David Wei, PhD, MS Novartis Pharmaceuticals Corporation	Impact of Adverse Events on Quality of Life in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors – Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study	Kathryn E. Flynn, PhD; Joan Clements, AA, ABA; Karen DeMairo, MHA; Jennifer Hiller, MSc; Nisha C. Hazra, PhD; Cristina Constantinescu, MA; Yan Meng, PhD; Dominick Latremouille-Viau, MA; Kejal Jadhav, B. Pharm, MS; Gabriel Marquez, MS; Daisy Yang, PharmD, BCOP; Andrea Damon, PhD; Islam Sadek, MD; Annie Guérin, MSc; Kelly Schoenbeck, MD	Outcomes and Health Services Research
126	Charmi Trivedi, MD Brown University	Nonbacterial Thrombotic Endocarditis In Early Stage Lung Adenocarcinoma	Alexander Gorzewski, MD; William Page, MD; Muhammad Azeem Khan, MD	Case Reports

General Poster Session II

Hosted by NCCN Oncology Research Program (ORP)

Session II Saturday, March 29

Breakfast 7:30 - 8:30 AM | Morning Break 9:45 - 10:05 AM

Lunch 11:55 AM - 1:10 PM | Afternoon Break 3:00 - 3:35 PM

Follow the Expert Guided Poster Tour

Open to all attendees. No pre-registration required. An NCCN Member Institution expert will lead a group of conference attendees and highlight research.

Meet by the posters
in the Exhibit Hall at 12:25 PM.

#	Presenting Author and Institution	Title	Co-Authors	Category
127	Xiao Wang, MD Yale Cancer Center/ Smilow Cancer Hospital NCCN Member Institution	A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era	Jessica B. Long, MPH; John Rothen, MS; Pamela R. Soulos, MPH; Timothy J. Robinson, MD, PhD; Carolyn J. Presley, MD, MHS; Sarah B. Goldberg, MD, MPH; Ronac Mamtani, MD, MSCE; Shi-Yi Wang, MD, PhD; Natalia Kunst, PhD; Shuangge Ma, PhD; Sida Huang, BS; Cary P. Gross, MD; Michaela A. Dinan, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
128	Daniel Thomas Jones, OMS-IV Touro University Nevada College of Osteopathic Medicine	Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (IRAEs) in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated with Immunochemotherapy	Hazem Aboaid, MD; Ramaditya Srinivasmurthy, OMS-IV; Kevin Nguyen, OMS-IV; Jason Ta, OMS-IV; Benjamin Tzer-Ming Chuang, MD; Rishi Kumar Nanda, OMS-III; Yin Mon Myat, MD; Kyaw Zin Thein, MD	Outcomes and Health Services Research
129	Ramaditya Srinivasmurthy, OMS-IV Touro University Nevada College of Osteopathic Medicine	Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs)	Hazem Aboaid, MD; Daniel Thomas Jones, OMS-IV; Kevin Nguyen, OMS-IV; Jason Ta, OMS-IV; Benjamin Tzer-Ming Chuang, MD; Rishi Kumar Nanda, OMS-III; Yin Mon Myat, MD; Kyaw Zin Thein, MD	Outcomes and Health Services Research
130	Ahmad Karkash, MD Indiana University Melvin and Bren Simon Comprehensive Cancer Center NCCN Member Institution	Impact of Early Palliative Care on Outcomes in Small Cell Lung Cancer	Weston He, MD; Mya Tran, PharmD; Julian A. Marin-Acevedo, MD; Misty Dawn Shields, MD, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
131	Justin W. Shi, MD Indiana University Melvin and Bren Simon Comprehensive Cancer Center NCCN Member Institution	Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Deathligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-mutant Lung Squamous Cell Carcinoma (LSCC)	Ahmad Karkash, MD; Weston He, MD; Mya T. Tran, PharmD; Yan Han, PhD; Misty Dawn Shields, MD, PhD; Julian A. Marin-Acevedo, MD	Clinical Oncology
132	Chawalit Chayangsu, MD, MSc Surin Hospital	Impact of the Surin One-stop Service (S.O.S) System on Reducing Patient Travel and Improving Cancer Treatment Access in Rural Thailand	Thiya Nusairam, BSN; Chalermchai Lertanansit, MD, MSc	Outcomes and Health Services Research
133	Yang Li, PhD Women's Hospital School of Medicine Zhejiang University	Neoadjuvant Chemotherapy Combined with Immunotherapy in Endometrial Cancer (NACI-EC)	Wei Wang, PhD; Dongxiao Hu, MD; Tingting Chen, PhD; Hui Wang, MD	Trials in Progress
134	Fardad Moshtagh Sisan, DO Valley Hospital Medical Center	Predictors of Brain, Bone, and Liver Metastasis in Lung Cancer: A Logistic Regression Analysis	Chris Pace, DO; Syed Akbarullah, MD; Scott Silver, DO	Epidemiology/Risks/Prevention
135	Melissa L. Santorelli, PhD Merck & Co., Inc	Initial Clinical Presentation (ICP) and Pre-diagnostic Journey During 18 Months Before a First Non-small Cell Lung Cancer (NSCLC) Diagnosis: US Retrospective Cohort Study	Molly Scannell Bryan, PhD; Ashwini Arunachalam, MPH, BDS; Xiaohan Hu, PhD, MPH; Ashleigh E. McBratney, MS; Connor Sweetnam, BS; Lori Boice, BS; Kristiana Wilkinson, MS; Ronda G. Broome, MS, MSHMI; Anna B. Berry, MD; Monica A. Izano, PhD, MS, MA	Outcomes and Health Services Research
136	Arpan Sahoo, BS University of South Florida Health Morsani College of Medicine	Pancreatic Cancer: Expediting Histopathological Diagnosis to Reduce Time to Treatment Initiation	Gabrielle Chin, HS; Laila Stancil, HS; Adrianna Oraiqat, BS; Pamela Hodul, MD; Sarah Hoffe, MD; Nicole Nardella, MS, BS	Outcomes and Health Services Research
137	Puneeth Iyengar, MD, PhD Memorial Sloan Kettering Cancer Center NCCN Member Institution	Real-world (rw) Characteristics, Treatment (tx) Patterns and Clinical Outcomes in Patients (pts) with Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Received Chemoradiotherapy (CRT)	Doreen A. Kahangire, MSc; Alice Wang, MSc; Kristin Hsieh, MD; Natalia Donner, MSc; Iqra Syed, MSc; Daniel Simmons, PharmD, MS; Anne C. Chiang, MD, PhD	Outcomes and Health Services Research

General Poster Sessions | Session II | Saturday, March 29 continued

#	Presenting Author and Institution	Title	Co-Authors	Category
138	Erin Connolly-Strong, PhD <i>Inocras</i>	Uncovering APOBEC Mutational Signatures in Cancer: The Power of Whole Genome Sequencing for Comprehensive Genomic Profiling	Ryul Kim, PhD; Brain Beak-Lok Oh, MD; Chunyang Bao, PhD; Jung Ah Kim, PhD; Eun Kyong Lee, PhD; Jeong-Hoon Lee, PhD; Amy Ackershoek, PharmD; Sangmoon Lee, MD, PhD; Minsuk Kwon, MD	Correlative/Genomic
139	Hassan A. Khalil, MD <i>Dana-Farber/Brigham and Women's Cancer Center/ Mass General Cancer Center</i> NCCN Member Institution	Characterization of Lung Cancer Shedding and Spread Through Air Spaces in Lung Adenocarcinoma	Guy B. Clark, BSc; Stacey P. Kwan, BS; Weiwei Shi, MD; Frank S. Henry, PhD; Steven J. Mentzer, MD; Akira Tsuda, PhD	Clinical Oncology
140	Caroline Raymundo, BS, MS <i>Fred Hutchinson Cancer Center</i> NCCN Member Institution	Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)	Niloufer Khan, MD; Kevin Molloy, MBBS, PhD; Julia Scarisbrick, MBBS; Susan Thornton, MBA; Cecilia Larocca, MD; Jennifer Chen, MD; David Cella, MD; Michi Shinohara, MD	Outcomes and Health Services Research
141	LeAnn Perkins, FNP-BC, DipACLM <i>Prisma Health Upstate</i>	Multi-Year Review of the Management of Patients in a High-Risk Breast Clinic	Marie Smith, MS; William Kirian, Candidate; BS; Gina Franco, MSN, NP-C, DipACLM; Joe J. Stephenson MD	Epidemiology/Risks/Prevention
142	David Wei, PhD, MS <i>Novartis Pharmaceuticals Corporation</i>	Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia	Kathryn E. Flynn, PhD; Joan Clements, AA, ABA; Karen DeMairo, MHA; Jennifer Hiller, MSc; Nisha C. Hazra, PhD; Cristina Constantinescu, MA; Yan Meng, PhD; Dominick Latremouille-Viau, MA; Kejal Jadhav, B. Pharm, MS; Gabriel Marquez, MS; Daisy Yang, PharmD, BCOP; Andrea Damon, PhD; Islam Sadek, MD; Annie Guérin, MSc; Kelly Schoenbeck, MD	Outcomes and Health Services Research
143	Fatima Ahmad, BS <i>Cedars-Sinai Medical Center</i>	Is Research Productivity Aligned with Public Interest regarding Diets and Cancer? A Comparison of Public Google Search Activity to Number of Academic Research Publications	Ameer Maya, BS; Nadine A. Friedrich, MD; Sanjay Das, MD; Pao-Hwa Lin, PhD; Stephen Freedland, MD	Outcomes and Health Services Research
144	Kelley Grealish, MS, ANP-BC <i>Dana-Farber/Brigham and Women's Cancer Center/ Mass General Cancer Center</i> NCCN Member Institution	Implementation of an Emergent Response System in an Urban Oncology Infusion Unit: A Quality Improvement Initiative	Jennifer Glorioso, RN, MSN; Michelle Knowles, MS, ANP-BC; Karoline Morrisey, RN, BSN; Ryanne Coulson, PA; Sara Hunter, RN, BSN; Jennifer Kennedy, RN, BSN; Marissa Pellegrino, RN, BSN; Lisa Quinn, PhD, AGACNP-BC; Frances Lu, BA, MPH	Quality Improvement
145	Ranjita Poudel, PhD <i>Moffitt Cancer Center</i> NCCN Member Institution	Evaluating the Effect of a Mindfulness-based Intervention on Metabolic and Immunological Biomarkers of Stress Among Caregivers of Allogeneic Hematopoietic Stem Cell Transplant Recipients: Trial in Progress	FNU Amisha, MD; Sierra Washington, MPH; Halle R. Smith, BA; Skye O. Dougan, MPH; Min-jeong Yang, PhD; Marilyn Horta, PhD; Farhad Khimani, MD; Christine Vinci, PhD	Trials in Progress
146	Christopher T. Su, MD, MPH <i>Fred Hutchinson Cancer Center</i> NCCN Member Institution	Association of Chimeric Antigen Receptor T-Cell Therapy and Social Vulnerability Index: A National View of Care Delivery Patterns	Emisa Nategh, PhD; Alireza Bolori, PhD	Outcomes and Health Services Research
147	Andrew L. Pierce, MD <i>Huntsman Cancer Institute at the University of Utah</i> NCCN Member Institution	A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients with Secondary CNS Relapsed DLBCL in the Modern Era	Izel Okcu, MD; Grzegorz Nowakowski, MD; Seda Tolu, MD; Jennifer Amengual, MD; Che Ross, PA-C; Jerome Graber, MD, MPH; Alli Bock, MD; Boyu Hu, MD; Daniel Ermann, MD	Outcomes and Health Services Research
148	Wei Tang <i>Xiangya Hospital Central South University</i>	CD13 as a Potential Membrane Marker in PSMA-Negative Prostate Cancer and First in Human Study of [18F]AIF-CD13-L1 PET/CT Imaging	Ming Zhou; Chenxi Lu; Lin Qi; Ye Zhang; Yongxiang Tang; Xiaomei Gao; Shuo Hu; Yi Cai, PhD	Clinical Oncology
149	Taimur Khalid, MS-IV <i>University of Nevada Las Vegas Kirk Kerkorian School of Medicine</i>	A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors	Hazem Aboaid, MD; Daniel Thomas Jones, OMS-IV; Jason Ta, OMS-IV; Ramaditya Srinivasamurthy, OMS-IV; Kenny Do, MS-III; Kevin Nguyen, OMS-IV; Karina Fama, OMS-IV; Rishi Kumar Nanda, OMS-III; Sarah Aamer, MD; Jo-Lawrence Bigcas, MD; Kyaw Zin Thein, MD	Outcomes and Health Services Research
150	Riccesha Hattin, DO <i>University of Nevada Las Vegas Kirk Kerkorian School of Medicine</i>	Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated with Amivantamab	Hazem Aboaid, MD; Abbas Hussain, MD; Savannah Schauer, MS-III; Tal Schlesinger, MS-III; Rory Twells, MS-III; Karl Aharonian, MS-III; Ryan Parto, MD; Rodd Rahmani, MD; Chalette Lambert-Swainston, MD; Daniel Thomas Jones, OMS-IV; Ramaditya Srinivasamurthy, OMS-IV; Kyaw Zin Thein, MD	Outcomes and Health Services Research

General Poster Sessions | Session II | Saturday, March 29 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
151	Syed Maaz Tariq, MD <i>White River Medical Center</i>	Hematologic Adverse Effects Profile of Immune Checkpoint Inhibitors: A Real World Pharmacovigilance Study Using FAERS Database	Shafaq Jawed, MD	Epidemiology/Risks/Prevention
152	Zhuoye Chen, MD <i>Zhejiang University School of Medicine Women's Hospital</i>	Extracellular Vesicles Evade the Antiangiogenic Effect of Bevacizumab in Ovarian Cancer	Conghui Wang, PhD; Mingxia Xu, MD; Tingjia Zhu, PhD; Yuehan Wang, PhD; Xiaodong Cheng, PhD; Xinyu Wang, PhD	Quality Improvement
153	Litta Justine, MBBS, MS, ENT, Mch <i>Amrita Institute of Medical Sciences and Research Centre</i>	Reconstructive Strategies For Maxillectomy Defects: A Single Centre Data on Surgical Approaches, Outcomes, and Morbidities	Abhishek Gugliani, MBBS, MS, ENT, DNB, Mch; Subramania Iyer, MS, ENT Mch; Krishnakumar Thankappan, MS, ENT, DNB, Mch; Jimmy Mathew, MS, Mch; Deepak Balasubramanian, MS, ENT, DNB, Mch; Lakshmi Ravunniarth Menon, MS, ENT, DNB, ENT; Tejal Patel, MS, ENT, Mch	Clinical Oncology
154	Alex Jiro Carsel, MD <i>Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute</i> NCCN Member Institution	Comparative Risk of Acute Kidney Injury Among Cancer Patients Treated with Immunotherapy Using Large-scale US Clinical Data	Arash Rashidi, MD; Jaime Abraham Perez, PhD; Elleson Harper, BS; Qian Wang, MD, MPH	Outcomes and Health Services Research
155	Purvish Trivedi, MPH <i>Moffitt Cancer Center</i> NCCN Member Institution	Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy	Shivanshu Awasthi, PharmD, MPH; Jasreman Dhillon, MD; Jong Park, PhD; Elai Davicioni, PhD; Alexander Hakansson, MPH; Seagle Liu, PhD; Esther Katende, MPH; Riley Smith, MPH; Kenneth Gage, MD; Ryan Burri, MD; Cesar Ercole, MD; Julio Pow-Sang, MD; Kosj Yamoah, MD, PhD	Clinical Oncology
156	Manu Prasad, MBA <i>Btech ZS Associates</i>	Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients	Tianyuan Hu, MPH; Daniel Young, PhD; Atharv Sharma, BE; Arrvind Sunder, MS; Arindam Paul, B Tech; Diganta Chowdhury, MEd	Best Practices in Implementation and Use of Clinical Practice Guidelines
157	Cheongin Rachel Im, MSN, RN <i>The University of Texas at Austin School of Nursing</i>	Symptom Management and Patient Outcomes in Cardio-Oncology Population: A Scoping Review	Oscar Y. Franco-Rocha, BSN, RN; Kavita Radhakrishnan, PhD, MSEE, RN	Outcomes and Health Services Research
158	Kirti Srivastava, MD <i>King George Medical University</i>	Hospital-Based Cancer Registry (HBCR) Data Analysis for Women at a Tertiary Care Center in North India	Divya Kukreja, MD; Mrinalini Verma, MD; Sumaira Qayoom, MD; Puneet Prakash, Mch; Shiv Rajan, Mch; Arun Chaturvedi, MS	Epidemiology/Risks/Prevention
159	Indraja Siripurapu, DM <i>Asian Institute of Gastroenterology</i>	Immunotherapy in Advanced Solid tumors – Real World Data from India	Vamshi Krishna M., DM; Naga Avinash Bonda, DM; Arif Mohammed Khan, DM	Outcomes and Health Services Research
160	Lei Xu, PhD <i>Fudan University School of Nursing</i>	A Correlation Research of Distress, Coping, and Quality of Life in Patients with Sarcoma	Yuanyuan Li, MS; Yikai Kong, BS; Maoting Tian, PhD candidate; Jiayang Zhang, BS; Ruiqi Shu, BS; Yiwen Chen, BS	Outcomes and Health Services Research
161	Tatiana Kashtanova, MS <i>Johns Hopkins Kimmel Cancer Center</i> NCCN Member Institution	Evaluation of Alternative Approaches to New Lesion Management and Measurable Disease Size Threshold on RANO-BM Response Assessment Following SRS for Brain Metastases	Andrew Keller, MD; Naren Ramakrishna, MD, PhD	Outcomes and Health Services Research
163	Alexander Rudich, BS <i>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</i> NCCN Member Institution	Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches	Natalie Johns, BA; Songzhu Zhao, MS; Kenneth Chian, BS; Po-lan Su, MD, PhD; Adam Khorasanchi, MD; Jinesh Gheeya, MD, PhD; Daniel Spakowicz, PhD; Lai Wei, PhD; Logan Roof, MD, MS; Asrar Alahmadi, MBBS; Regan Memmott, MD, PhD; Jacob Kaufman, MD, PhD; Carolyn Presley, MD; Kai He, MD, PhD; Peter Shields, MD; Christian Rolfo, MD, PhD; David Carbone, MD, PhD; Mingjia Li, MD; Dwight Owen, MD, MS	Clinical Oncology
164	Ahmad Alhalabi, MD <i>Cleveland Clinic Florida</i>	The Effect of Delay of Adjuvant Chemotherapy on the Overall Survival in Early-Stage Breast Cancer	María Herrán, MD; Kaylee Sarna, MSc; Theresa Abdo, MD; Rami Tfayli, MD; Zeina Nahleh, MD, FACP	Clinical Oncology
165	Rami Tfayli, MD <i>Cleveland Clinic Florida</i>	Predictors of Survival in Breast Cancer with Brain Metastases: A Multi-Center Institutional Experience	Ali Hijazi, MD; Mohamed Mohanna, MD; Kaylee Sarna, MSc; Saad Sabbagh, MD; María Herrán, MD; Saffett Gülenyüz, MD; Razan Mohanna, MD; Rashid Mahrous, MD; Surabhi Ranjan, MD; Zeina Nahleh, MD, FACP	Clinical Oncology
166	Maria Herran, MD <i>Cleveland Clinic Florida</i>	Immune-Related Adverse Events in Women with Early and Advanced Triple-Negative Breast Cancer treated with Pembrolizumab: A Multi-Center Analysis	Ahmad Alhalabi, MD; Kaylee Sarna, MSc; Theresa Abdo, MD; Rami Tfayli, MD; Zeina Nahleh, MD, FACP	Clinical Oncology

General Poster Sessions | Session II | Saturday, March 29 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
167	Jowan Al-Nusair, MD Marshall University Joan C. Edwards School of Medicine	Metastatic Neck Involvement in Oral Squamous Cell Carcinoma: A Retrospective Clinicopathological Study	Medyan Al Rousan, BDS, MSc; Moh'd Masoudi, MD; Mahmoud Abdallah, MD	Clinical Oncology
168	Ann Cao-Nasalga, MBA Stanford Cancer Institute NCCN Member Institution	Palliative Care in Action: Educating Through Storytelling	Olivia Tigre Nerimora, MHA; Ashley Bragg, BS; Grant Smith, MD	Quality Improvement
169	Daniel Simmons, PharmD, MS AstraZeneca Pharmaceuticals LP	Characterizing Influences to Multidisciplinary Team Care in Resectable Non-small Cell Lung Cancer: A Qualitative Study	Emily Mulvihill, MBA; Nicole Kashine, MPH; Stephanie Tomazin, MPH; David Cornwall, MBA; Silas Hartley, PhD; Stephanie Loomer, MS; Nicholas Theilen, PhD; Tiernan Mulrooney, PhD; Melody Hughes, MS RN; Debora Bruno, MD, MS	Outcomes and Health Services Research
170	Seohyuk Lee, MD Beth Israel Deaconess Medical Center	Models and Outcomes of Multidisciplinary Clinics in Lung Cancer	Miguel M. Leiva Juarez, MD, MSE; Stuart M. Berman, MD; Mujtaba Mubashir, MD; Brian M. Russell, MD; Deepa Rangachari, MD; Jessica A. Zerillo, MD, MPH	Quality Improvement
171	Manavjot Singh Dayanand Medical College and Hospital	Frequency and Pattern of 30-day Readmissions in Cancer Patients with C. Difficile Infection	Rupak Desai, MBBS; Akhil Jain, MD	Epidemiology/Risks/Prevention
172	Amara Sofia, MBBS, MD New York Medical College School of Medicine	Trends in Depression and its Unequal Burden in Cancer Survivors with Socioeconomic Disparities	Ahmad Alhormaid; Nancy K. Ganatra; Aditya Sanjeevi; Rupak Desai, MBBS; Akhil Jain; Rishika Trivedi	Outcomes and Health Services Research
173	Zin Myint, MD University of Kentucky Medical Center	Risk of Venous and Arterial Thrombosis as Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis	Kris Varothai, PhD; Megan Foley, BSN, RN; Donglin Yan, PhD	Outcomes and Health Services Research
174	Senmi Qian, MD Zhejiang University School of Medicine	Mapping Common Oncogene Protein-Protein Interactions to Discover New Targets in HRD-Negative Ovarian Cancer	Qiang Liu, PhD; Yuhua Liu, MD; Xiaodong Cheng, MD; Junbin Qian, PhD	Correlative/Genomic
175	Amy Ackershoek, PharmD, MBA Inocras	Identification of an Elusive CBFA2T3-GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing	Yuna Lee, MD; Sunwoo Yoon, MD; Juyeon Lee, MD; Hyun Jin Park, MD; Bo Kyung Kim, MD; Kyung Taek Hong, MD; Ji Hoon Phi, MD; Ji Won Lee, MD; Se Hoon Kim, MD; Ryul Kim, PhD; Hyoung Jin Kang, MD; June-Young Koh, MD; Jung Yoon Choi, MD	Correlative/Genomic
177	Yikai Kong, BS Boston University College of General Studies	The Correlation of Resilience, Family Hardiness and Quality of Life of Patients with Soft Tissue Sarcoma and Family Caregivers Based on a Binary Perspective	Lei Xu, PhD; Ruiqi Shu, BSN; Yuan Yuan Li, MS; Maoting Tian, Jiayang Zhang, BSN; Yiwen Chen, BSN	Outcomes and Health Services Research
178	Adrianna Oraiqat, BS Moffitt Cancer Center NCCN Member Institution	Exocrine Pancreatic Insufficiency (EPI) in Pancreatic Cancer Patients: Increasing Awareness and Screening	Nicole Nardella, MS; Nathan Gilchrist, BS; Sarah Goodchild, BS; Dena Berhan, BS; Laila Stancil; Pamela Hodul, MD	Quality Improvement
179	Natalie Perle Bransky, MD UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution	Carfilzomib-induced Thrombotic Microangiopathy in Multiple Myeloma	Nikhita Kathuria-Prakash, MD; Mary Sehl, MD, PhD	Case Reports
180	Jason Ta, OMS-IV Touro University Nevada College of Osteopathic Medicine	A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Hand-Foot Skin Reaction (HFSR) or Palmar-Plantar Erythrodysesthesia (PPE) in Patients with Cancers Treated with Fruquintinib	Benjamin Tzer-Ming Chuang, MD; Hazem Aboaid, MD; Daniel Thomas Jones, OMS-IV; Ramaditya Srinivasmurthy, OMS-IV; Kevin Nguyen, OMS-IV; Rishi Kumar Nanda, OMS-III; Yin Mon Myat, MD; Kyaw Zin Thein, MD	Outcomes and Health Services Research
181	Joy Bartholomew, MSN Cancer & Hematology Centers	Improving Under-represented Rural Population Access to Oncology Care in the Community	N/A	Outcomes and Health Services Research
182	Tao Zhang, MD Women's Hospital School of Medicine Zhejiang University	Identification of Predictors for Cancer-Specific Survival in Patients with Stage I Vulvar Squamous Cell Carcinoma: Evidence from the Staging Group with the Greatest Population	Zhuoqun Lin, Master; Ziyu Xing, Master; Xiaodong Wu, MD; Fenfen Wang, MD; Xiaodong Cheng, MD	Epidemiology/Risks/Prevention

General Poster Sessions | Session II | Saturday, March 29 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
183	Rachel Lam, MSc, BSW, RSW <i>Queen Mary Hospital</i>	A Structured Approach in Suicide Prevention – Safety Plan Intervention for Cancer Patients	Cheuk Yan Karin Chu, MA, BSW, RSW; Sin Ling Sharon Mo, MSc, BSW, RSW; Kwok Keung Yuen, MBChB, FRCP, FHKCR, FHKAM, MSc; Wai Kwan Steven Siu, MBBS, FRCP, FHKCR, FHKAM, MSc; Sum Yin Ann Chan, MBBS, MResMed, FRCP, FHKCR, FHKAM	Clinical Oncology
184	Gabrielle Librizzi, MD <i>Stony Brook University Hospital</i>	Cost-effectiveness of Dose Reduction of Antibody-drug Conjugates for Breast Cancer	Jules Cohen, MD	Clinical Oncology
185	Matthew Leopold Moskal <i>Watson Clinic, LLP</i>	Compliant Care and Quality Outcomes in Multiple Myeloma	Sunil Rohatgi, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
187	Rani Singh, PhD <i>Hologic, Inc.</i>	Evaluation of Performance, Safety, and User Satisfaction of the Brevera® Breast Biopsy System: A Multicentre Study	Sharath Kandhi, MD, PhD; Muhammad Waqas, BE, MBA; Regina Hooley, MD	Quality Improvement
188	Stephanie Lourdes Echeverria, MPH, MBS <i>Midwestern University Arizona College of Osteopathic Medicine</i>	Evaluation of a Patient Navigation System on Cancer Treatment Milestones in a Rural Cancer Center	John Ashurst, DO, Ded; Edgardo Rivera, MD; Anthony Santarelli, PhD; Diana Lalitsasivimol, PhD	Outcomes and Health Services Research
189	Apirak Nguanboonmak, MD <i>Makarak Hospital</i>	Attitudes and Knowledge of Primary Human Papilloma Virus Testing Among Women Attending Primary Healthcare	N/A	Epidemiology/Risks/Prevention
190	Naresh Ramarajan, MD <i>Navya Care</i>	Validating Navya Earthshot: An AI Driven Point of Care Solution for Guideline Adherent Treatment Planning in a Decentralized Cancer Care Model	Umesh M. Mahantshetty, MD; Shilpa Kandipalli, MD; Guru Raghavendra Naik, MD; Motepalli Panduranga Kumari, MD; Padmanaban Srinivasan, MD; Raviteja Miriyala, MD; Shveta Sharma, NCG, AP; Ramya B; Nagashayana Gampalahalli, MD; Arpitha Chinnu Sabu, MD; Rhea Mehta; Dolorosa Fernandes, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
191	Angela Karina Sato Espinoza, MD <i>Mayo Clinic Comprehensive Cancer Center NCCN Member Institution</i>	Low Serum Pseudocholesterase Level Predicts HCC Mortality as Accurately as the ALBI or MESIAH Score	Perapa Chotiprasidhi, BS; Joseph J. Larson, MS; Lewis R. Roberts, MB, ChB, PhD; Kirk J. Wangensteen, MD, PhD	Clinical Oncology
192	Luis Antonio Cancel, MD <i>Monterrey Institute of Technology and Higher Education</i>	Endobronchial Malignant Granular Cell Tumor (MGCT) with BRAF Mutation: Case Report	Javier Alejandro Martinez Moyano, MD; Erik Edmundo Perez Ramos, MD; Andrea Pechir Cerrillo, MD, MSc	Clinical Oncology
193	Rishabh Arun Vashisht, MBBS NRI <i>Academy of Science Medical College</i>	The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Predicting Clinical and Survival Outcomes and Treatment Response for Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR-T) Therapy	Nency Kashyap Ganatra, MD; Diksha Sanjana Pasnoor, MBBS; Mohit Mirchandani, MD; Beenish Najam, MBBS; Akhil Jain, MD; Rupak Desai, MBBS	Clinical Oncology
194	Ese-Onosen Omojuanfo, BS <i>Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Member Institution</i>	The Impact of Cancer Treatment on Hearing Loss	Keri Plevniak, MS; Richard Chahine, MD; Jaime A Perez, PhD; Alex Eishingdrelo, BS; Qian Wang, MD, MPH; Melinda Hsu, MD, MS	Outcomes and Health Services Research
195	Adamsegd Isac Gebremedhen, MD <i>Marshall University Joan C. Edwards School of Medicine</i>	Epidemiology and Outcomes of Ventricular Arrhythmias in Patients with Hypercalcemia of Malignancy: A Population-Based Study	Mamdouh Souleymane, MBBS; Ibrahim Shanti, MD; Yonas Fette, MD; Samson Tekla, MD; Stephen Roy, MD; Donald R. Lynch, Jr, MD, MSCI	Outcomes and Health Services Research
196	Thanmai Reddy Thugu, MBBS, MD <i>New York City Health and Hospitals Metropolitan</i>	MiR-31 as a Predictive Biomarker of Cetuximab Efficacy in Metastatic Colorectal Cancer Patients	Muskan Jain, MBBS; Neeharika John Madhavaram, MBBS; Neha Singh, MBBS; Sonali Dash; Ahmad Alhomaïd, MD; Sai Gautham Kanagala, MBBS; Laxman Yashwant Byreddi, MBBS, MD; Akhil Jain, MD; Rupak Desai, MBBS	Clinical Oncology
197	Ryan McWhorter, BA <i>UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution</i>	The RKIP/HIF-1 Axis in Cancer Immune Evasion	Benjamin Bonavida, PhD	Pre-Clinical Oncology
198	Haritha Mopuru, MD <i>University of North Dakota</i>	Hydrocortisone Instead of Dexamethasone as Premedication for Paclitaxel	Amit Panwalkar, MD; Abe Eric Sahnoun, PhD, MS	Best Practices in Implementation and Use of Clinical Practice Guidelines

General Poster Sessions | Session II | Saturday, March 29 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
199	Samuel Crawford, PhD <i>AbbVie</i>	Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKI) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractory (R/R) Settings	Huimin Li, MA; Bhavini Srivastava, MSc; Pam Martin, PhD; James Gahn, BS; Shafiq Bacchus, PharmD; Olga Ryan, DrPH, MPH, MBA; Monika Salkar, PhD	Outcomes and Health Services Research
200	Amye J. Tevaarwerk, MD <i>Mayo Clinic</i> <i>Comprehensive Cancer Center</i> <i>NCCN Member Institution</i>	Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-time Using the Electronic Health Record (EHR)	Clare Gatten, MA; Teshome Simret, RN; Karthik Giridhar, MD; Jamie Carroll, APRN, CNP, MSN; Pooja Advani, MD; Sarayana Chumsri, MD; Zhaohui Jin, MD; Sumithra Mandrekar, PhD	Quality Improvement
201	Kimberly McGregor, MD <i>Intermountain Healthcare</i>	Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning	Michal Harel, PhD; Adam P. Dicker, MD; Janakiraman Subramanian, MD; Edgardo S. Santos, MD; Itamar Sela, PhD; Yehonatan Elon, PhD; David R. Gandara, MD	Correlative/Genomic
202	Kylee Flagg, MCIS, RN <i>The US Oncology Network</i>	Navigating Barriers to ePRO Implementation in Community-Based Oncology Practices	Christine Bates, MSN, RN; Judi Payne, BSN	Quality Improvement
203	Yite Xue, PhD <i>Zhejiang University School of Medicine</i>	Hyperthermia Enhancing the Effect of Olaparib by Inducing Ferroptosis in Ovarian Cancer	Taotao Yin, PhD; Lingfang Wang, PhD; Zhuoqun Lin, MS; Xiaodong Cheng; Hui Wang	Quality Improvement
204	Tejas Karawadia, MD <i>Cancer Specialists of North Florida</i>	Impact of PD-L1 Expression on Immune-Related Adverse Events (irAEs) in Non-Small Cell Lung Cancer (NSCLC): Real-world Data From Community Oncology Practice	Hardik Chhatrala, MD; Avani Shah; Audrey Bui; Min Chae; Bijoy Telivala, MD	Clinical Oncology
205	Obadia Venance Nyongole, MD <i>Mmed Muhimbili University of Health and Allied Sciences School of Medicine</i>	Quality of Data for Improvement of Prostate Cancer Services to Patients Treated at Tertiary Hospitals in Tanzania	Castory Munishi, BPharm, MSGH; Nathanael Sirili, MD, PhD; Deodatus Kakoko, Bsc, PhD; Gasto Frumence, BA, PhD; Daudi Simba, MD, PhD; David Urassa, MD, PhD; Bruno Sunguya, MD, PhD	Quality Improvement
206	Chandan Sona Bevara, MBBS <i>Brooklyn Cancer Care</i>	Anemia Severity: A Missed Prognostic Opportunity in Multiple Myeloma	Anmol Heer, MBBS; Mohd Faiz, MD; Vaasu Bhardwaj, MBBS; Semra Korkmaz, MD; Kshitij Bhardwaj, MBBS; Naresh Reddy Mudireddy, MBBS; Ademi Mahambetkul, MD; Yerbolat Umbetov, MD; Gursharan Kaur, MBBS; Ratesh Khillan, MD	Clinical Oncology
207	Barbara Schneider, PhD, MBA <i>Advarra</i>	The New Threshold for Independence in Data Monitoring Committees (DMCs)	N/A	Quality Improvement
208	Ahmed Fahmy Mandisha, MSc, MRCS <i>University Hospital of Wales</i>	Surgical Timing and its Effect on Disease Progression in Non-Small Cell Lung Cancer: A Stage-Specific Analysis	Stamatina Koskolou, MD, MRCS; Mohammad Ibrahim, MBCh, MSc, MD, MRCS; Kamran Inamdar, MBBS, MSc, PhD; Kamrul Hasan, MBCh, MSc, MD, MRCS; Joshua Samuel, MBBS; Anfal Farah, MBBS, MRCS; Abdelhadi Isamil, MBBS, MRCS; Musab Mohammed, MBBS, MRCS; Tom Combella, Meng(hons), MBCh, FRCS, PGDip; Malgorzata Kornaszewska, MD, PhD; Aini Pirtnieks, MD; Vasilios Valtzoglou, MD, MSc	Clinical Oncology
209	Marwa Youssef, MBBS, MSc, MRCS <i>Sultan Qaboos Comprehensive Cancer Center</i>	Survival Outcomes in Breast Cancer Patients with Diseased Axillary Lymph Nodes: The Role of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy	Suaad AlAghbari; Hasan Al-Sayegh, MBChB, MPH; Khalid Albaimani; Badriya AlQassabi; Adil AlAjmi, MBChB, FRCSI, FRCS, MD	Clinical Oncology
210	Chalothorn Wannaphut, MD <i>University of Hawaii</i>	Racial Disparities in Non-small Cell Lung Cancer Survival Outcomes: A Systemic Review and Meta-Analysis	Ben Ponvilawan, MD; Chanakarn Kanitthamniyom, MD; Narathorn Kulthamrongri, MD; Vitthapong Prasitsumrit, MD; Phuuwadith Wattanachayakul, MD; Manasawee Tanariyakul, MD; Sakditad Saowapa, MD	Outcomes and Health Services Research
211	Bohdan Baralo, MD <i>Virginia Commonwealth University</i>	Clinical Characteristics and Prognosis Associated with Low PSA in Patients with De Novo Metastatic Hormone Sensitive Prostate Cancer	Natasha N. Dziarnowski, MD; Peter T. Daniels, MD; Cody A. McIntire, MD; Morgan M. Puglisi, MD; John W. Melson, MD; Asit K. Paul, MD	Outcomes and Health Services Research
213	Davin Turku, MD <i>Brooklyn Hospital Center</i>	Prostate Cancer and Geography: How Location Affects In-hospital Outcomes? A Nationwide Analysis	Jayalekshmi Jayakumar, MD; Manasa Ginjupalli, MD; Fiqe Khan, MD; Surbhi Singh, MD; Arya Mariam Roy, MD	Epidemiology/Risks/Prevention
214	Bradley Ventayen, BS <i>California University of Science and Medicine School of Medicine</i>	Analyzing Demographic Trends and Cancer Resource Support Centers Affecting the Cancer Community in the Inland Empire	Francesca Johnson, BS; Nicole Holder, BS; Emmanuelle Morin, BS; Jack Angeles, BS; Erik Buetow, BS; Francesca Bossone, BS; Bonnie Blackman, BS; Sachin Reddi, BS; Jonathan Pai, BS; Joël Arvizo-Zavala, PhD, MEd, CHES	Outcomes and Health Services Research

General Poster Sessions | Session II | Saturday, March 29 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
215	Dominic van Loggerenberg <i>Netcare Milpark Hospital</i>	Benefits Of Telemedicine In Oncology Multi-Disciplinary Feedback	Charl van Loggerenberg, MBChB, MBA; Carol-Ann Benn, MBChB; Bernardo Rapoport, MMed; Tanya Volschenk	Bioinformatics/Information Technology Sciences
216	Mahima Prakash MD, PharmD <i>JSS College of Pharmacy Mysore</i>	A Randomized Controlled Trial to Assess the Impact of Omission of 5-Fluorouracil Bolus Among Stage 2 and 3 Gastrointestinal Cancer Patients	Kiran P. K., MBBS, MD, DNB	Trials in Progress
217	Angelo Pirozzi, MD <i>Mayo Clinic Comprehensive Cancer Center NCCN Member Institution</i>	Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)	Celine Hoyek, MD; Binbin Zheng, MD; Naoko Lida, MD; Ryne Ramaker, MD, PhD; Seyi Abidoye, MD; Cody Eslinger, MD; Taro Shibuki, MD; Christina S. Y. Wu, MBChB, MD; Mohamad Bassam Sonbol, MD; Daniel H. Ahn, MD; Mitesh Borad, MD; Masafumi Ikeda, MD; Yoshiaki Nakamura, MD, PhD; Lorenza Rimassa, MD; Takayuki Yoshino, MD, PhD; John Strickler, MD; Tanios Bekail-Saab, MD	Clinical Oncology
218	Sai Gautham Kanagala, MBBS <i>Metropolitan Hospital Center</i>	miR-126 in Prostate Cancer: A Systematic Review of Its Impact on Cancer Progression and Treatment	Neha Singh, MBBS; Diksha Sanjana Pasnoor, MBBS; Sandeep Singh, MBBS, MRCP; Akhil Jain, MD; Rupak Desai, MBBS	Clinical Oncology
219	Anuja V. Abhyankar, MD <i>Roswell Park Comprehensive Cancer Center NCCN Member Institution</i>	Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard of Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) with Prior Clinical Benefit to Pembrolizumab Monotherapy	Myung-ju Ahn, MD; Grace K. Dy, MD	Clinical Oncology
220	Kriti Dhamija, MD <i>Allegheny Health Network</i>	Analyzing the Prognostic Significance of Common Mutations in Pancreatic Cancer (PC) via Next Generation Sequencing (NGS)	Rachel DiLeo, DO; Kojo frimpong Awuah, MD; Harmeet Kharoud, MD, MPH; Dulabh Monga, MD	Correlative/Genomic
221	Andrew Abdelmessih, BS <i>ZS Associates</i>	Impact of Absence of Adjuvant Treatment on Patient Outcomes – Real World Evidence for Gastric Cancer	Manu Prasad, MBA, Btech; Nate Lear, MS, BS; Prashant Poddar, MBA, MS; Atharv Sharma, BE; Darshan Gokalgandhi, BTEch; Ashutosh Naudiyal, BTEch	Outcomes and Health Services Research
222	Jaison Lawrence Alexander Santhi, MD <i>Mercy Fitzgerald Hospital</i>	Epidemiology and Prognostication of Malignant Glomus Tumor	Hassan Ali, MD, MBBS; Elizaveta Bodrova, MD; Krishna Desai, MD; Satya Durugu, MD; Shammas Bajwa, MD; Alexandra Georgiana Boc, MD; Rajesh Thirumaran, MD	Epidemiology/Risks/Prevention
223	Jaison Lawrence Alexander Santhi, MD <i>Mercy Fitzgerald Hospital</i>	Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators	Hassan Ali, MD; Charan Thej Reddy Vegivinti, MD; Elizaveta Bodrova, MD; Mansi Mehta, MD; Reema Sara Varghese, MBBS; Varsha Sriram, MD; Rajesh Thirumaran, MD	Epidemiology/Risks/Prevention
225	Vineet Polineni, DO <i>Jefferson Health</i>	Clinical Outcomes for Medicare Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample	Danielle C. Thor, DO, MAUB; Tony Elias, MS; Ben Brik, DO	Outcomes and Health Services Research
226	Vineet Polineni, DO <i>Jefferson Health</i>	Clinical Outcomes for Medicaid Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample	Danielle C. Thor, DO, MAUB; Tony Elias, MS; Ben Brik, DO	Outcomes and Health Services Research
227	Nina Neill, MD <i>Inova Fairfax Hospital</i>	A MET Amplified Metastatic Esophageal Adenocarcinoma Demonstrates Response to the MET Inhibitor Capmatinib	Timothy Cannon, MD; Raymond Wadlow, MD	Case Reports
228	Krishna Kishore Anne, MD <i>New York City Health and Hospitals Corporation</i>	Langerhans Cell Histiocytosis: Presenting as Polyuria, Polydipsia, and Multiple Skull Lesions.	Ani Gvajaia, MD; Maria Fernanda Albuja Altamirano, MD	Case Reports
229	Sahithee Alekhya Batchu, BS <i>UCSF Helen Diller Family Comprehensive Cancer Center NCCN Member Institution</i>	Vascular Endothelial Growth Factor Inhibitor-induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient	Yue Ma, MD; Sue Yom, MD, PhD; Chase Heaton, MD; Alain Algazi, MD	Case Reports
230	Dhauna Karam Prasad, MBBS, MD <i>Mayo Clinic Comprehensive Cancer Center NCCN Member Institution</i>	Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC): A Mayo Clinic Multidisciplinary Approach to Treatment	Kimberly S. Corbin, MD; Tina Hieken, MD; Samir Mardini, MD; Malvika Solanki, MBBS, PhD; Svetomir Markovic, MD; Mathew Block, MD; Ciara O'sullivan, MBChB	Case Reports
231	Adrese Michael Kandahari, MD <i>Westchester Medical Center</i>	Paraneoplastic Syndrome in Undifferentiated Pleomorphic Sarcoma Demonstrates Acquired Antithrombin III Deficiency as Risk Factor for Cancer-related Morbidity	Carmelo Puccio, MD	Case Reports

General Poster Sessions | Session II | Saturday, March 29 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
232	Yu-Han Chen, MD <i>Englewood Hospital and Medical Center</i>	Worsening COPD from Hyperviscosity: A Case Report of Waldenström Macroglobulinemia	Isarapong Rattana, MD	Case Reports
233	Chanakarn Kanitthamniyom, MD <i>Texas Tech University Health Sciences Center School of Medicine</i>	Bilateral Pleural Effusion as a Presentation of Multiple Myeloma: A Case Report	Isarapong Rattana, MD	Case Reports
234	Joseph Edmund, MD <i>Marshfield Clinic Health System</i>	Double Whammy: Concurrent Presentation of Mantle Cell Lymphoma and Hairy Cell Leukemia	Liz Joemon Thaliath, MD	Case Reports
235	Chanmi Lee, MD, PhD <i>Beth Israel Deaconess Medical Center</i>	A Case of Stage IV NSCLC with MET exon 14 Mutation with Durable Response to MET inhibitor Following Cessation of Therapy due to Toxicity: Insights for Treatment Strategies	Emmeline Academia, PharmD, BCOP; Page C. Widick, MD	Case Reports
236	Alison Jane Meyers, BA <i>Brown University Warren Alpert Medical School</i>	Pneumocephalus in the Setting of Endometrial Adenocarcinoma: A Case Report	Kaavya Mandi, DO	Case Reports
237	Sai Sudha Valisekka, MD <i>University of Minnesota Medical Center Fairview</i>	Advanced Fibrosis, TP53 Variants, and Erythroid Differentiation: Diagnostic Harbingers of ERCC6L2-Related Bone Marrow Failure Syndrome?	Meghan E. Lindstrom, MD; Olivia Jeannine Michel, MS, CGC; Naveen Premnath, MD; Craig E. Eckfeldt, MD; Roy L. Kao, MD	Case Reports
238	Vasu Munjapara, MD <i>University of Michigan Rogel Cancer Center NCCN Member Institution</i>	Treatment of HER2-Positive Breast Cancer with Leptomeningeal Metastases with Intrathecal Trastuzumab	John Rice, PhD; Lindsay Robell, MD; Kelsey Peters, MD; Denise Leung, MD, MSc; Yoshie Umemura, MD; Aaron Mammoser, MD, MS; Aki Morikawa, MD, PhD; Larry Junck, MD	Case Reports
239	Alexander Konopnicki, DO <i>The University of Texas Medical Branch at Galveston</i>	A Case Series of Immunotherapy-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis	Kaihei Masuda, MD; Mathews Roy, MD; Saad Sidiq, DO; Jeremy Bergman, DO; Malvika Ramesh, MD; Tejo Musunuru, MD	Case Reports
240	Xiaowei Malone, DO, PhD <i>AdventHealth Tampa</i>	Delayed Detection of Liver Metastasis in Granulosa Cell Tumor Due to Healthcare Disparities: A Case Report and Literature Review	Otto Walter, MD; Kenneth Snell, MD	Case Reports
241	Melany Denise Medina, MD <i>Axxis Hospital</i>	Gastric-Type Mucinous Endocervical Adenocarcinoma: A Case Report and Literature Review	Suarez L.; Puente L	Case Reports
242	Charmi Trivedi, MD <i>Brown University</i>	Avapritinib Induced Pseudoprogression in a Gastrointestinal Stromal Tumor with a PDGFRA exam 18 842 Mutation	Timothy Murtha, MD, MHS; Zane Zaidi; Howard Safran, MD	Case Reports
243	Veronika Stefanishina, MD <i>New York City Health and Hospitals South Brooklyn Health</i>	A Rare Tumor Presentation in a Postpartum Female: Case Report of Malignant Peripheral Nerve Sheath Tumor Accompanying Neurofibromatosis Type I Diagnosis	Sabrina Elliott, MSc; Sushant Remersu, MD	Case Reports
244	Thomas Kirby, DO <i>Carolinas Medical Center</i>	A Therapeutic Conundrum: Malignancy-Associated Thrombotic Thrombocytopenic Purpura (TTP)	Natalie J. Reed, DO	Case Reports
245	Jason Huynh, MD <i>UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution</i>	Durable Response to Immunotherapy Rechallenge with Double Immunotherapy for a Patient with Advanced Non-small Cell Lung Cancer	Rui Li, MD, PhD; Daniel S. Shin, MD, PhD	Case Reports
246	Dileep Kumar Mandali, MD <i>Tulane University School of Medicine</i>	Differentiation Syndrome Masked as Encephalopathy in Patient with Recurrent Acute Myeloid Leukemia (AML)	Nicoy Downie, MD	Case Reports
247	Sharanya Tripathi, MD <i>Saint Vincent Hospital</i>	Socioeconomic and Clinical Determinants of Survival in Young Breast Cancer Patients: A Population Based Study	Charmi Bhanushali, MD; Kalaivani Babu, MD; Srinishant Rajarajan, MD; Jayalekshmi Jayakumar, MD; Vidhi Bhanushali, MBBS; Arya Mariam Roy, MD	Epidemiology/Risks/Prevention
248	Seham Abdelkhalek, MBBS, MD, PhD <i>King Abdullah Medical City</i>	Hypofractionated Postmastectomy Irradiation During COVID-19: Safety, Efficacy, and Patient-centered Care - A Single Institution Experience	Salwa Fathy, MBBS, MD, PhD; Nasser Al-Dhaibani, FRCPC; Maha Alidrisi, FRCPC; Duaa Alhawi, MD; Mazen Al-Gaoud, MD	Clinical Oncology



Kite and Gilead are proud to support the National Comprehensive Cancer Network and the 2025 Annual Conference



For more information, please visit www.KitePharma.com and www.Gilead.com.

GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. Kite and the Kite logo are trademarks of Kite Pharma, Inc.



NCCN Virtual Reimbursement Resource Room

Learn about patient assistance and reimbursement programs available.

Search by:

- Cancer Type or Supportive Care Indication
- Drug Name
- Reimbursement Program



Access for FREE online or via the app!
NCCN.org/reimbursement

Help people
living with cancer.
You can provide support for
FREE RESOURCES
and **INNOVATIONS**
IN ONCOLOGY RESEARCH.

NCCNFoundation.org/Donate



Save These Dates!

NCCN 2025 Annual Congress: Hematologic Malignancies™

Friday, October 10 – Saturday, October 11, 2025

New location!

Hilton San Diego Bayfront, San Diego, CA

NCCN 2026 Nursing Program: Advancing Oncology Nursing™

Thursday, March 26, 2026

Caribe Royale Orlando, Orlando, FL

NCCN 2026 Annual Conference

Friday, March 27 – Sunday, March 29, 2026

Caribe Royale Orlando, Orlando, FL

Visit NCCN.org/events for more information.

For patients with
earlier-stage cancer,

I am on a
MISSION
to
CURE

Though your goal is to treat with a curative intent, you recognize that a cure is not possible for every patient.¹ That is why it's important to partner with your multidisciplinary team (MDT) to develop treatment plans, including consideration of systemic therapies, for appropriate patients with earlier-stage cancers.

Collaborate with your MDT to explore treatment options, including systemic therapies, to help achieve your goals.

Scan to explore more about earlier-stage treatment considerations or visit
mission2cure.com



Reference: 1. American Cancer Society. How is chemotherapy used to treat cancer? Last revised November 22, 2019. Accessed November 14, 2024. <https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy/how-is-chemotherapy-used-to-treat-cancer.html>

Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-KEY-09065 11/24

Actor Portrayal